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ABSTRACT 
 
More than 350 million people are chronic hepatitis B virus (HBV) carriers. Viral 
covalently closed circular DNA (cccDNA) persists as a replication intermediate 
and can remain dormant. Current HBV therapeutics do not eradicate viral 
cccDNA reservoirs. Transcription activator-like effector nucleases (TALENs) 
target and cleave specific DNA sequences, and have shown promise as 
antiviral agents. Here we propose TALEN-mediated homology directed 
disruption and silencing of the cccDNA. The designer TALENs introduce 
double stranded breaks (DSBs) at the HBV cccDNA core and surface ORFs, 
which activate the non-homologous end joining (NHEJ) and homology directed 
repair (HDR) cellular repair pathways. We utilise the HDR process to introduce 
specific mutations at the TALEN cleavage sites. Here we facilitate integration 
of a HBV-targeting artificial primary micro RNA (pri-miR) mimic into the HBV 
genome by co-introducing TALENs and donor template strands that contain a 
pri-miR cassette flanked by sequences that are homologous to the TALEN 
target sites. Integration of the donor sequences was evaluated by PCR and 
disruption of HBV replication was evaluated using ELISA. HBsAg knockdown 
when targeting the surface and core targets was 94% and 63% respectively, a 
significant improvement on use of TALENs alone. PCR analysis and 
sequencing confirmed successful integration of donor sequences into the HBV 
core and surface target sites, verifying that HBsAg knockdown is as a result of 
sequence insertion and possible pri-miR-mediated silencing of HBx. In 
conclusion, integration of an artificial DNA sequence at specific HBV target 
sites was demonstrated and the synergistic activity of TALENs and donor 
template strands shows promising anti-HBV abilities. Results of this study 
provide the means to improve targeted disruption of HBV DNA by TALEN 
constructs. Moreover, the potential for combining different anti-HBV gene 
therapies to result in better viral suppression is demonstrated. 
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1. Introduction 
 
1.1 Hepatitis B virus epidemiology and pathogenesis 
 
More than 350 million people are chronic hepatitis B virus (HBV) carriers (1, 2). 
This presents a major public health challenge, as exposure to HBV can result 
in either acute or chronic liver infection. In adults HBV is predominantly 
transmitted through blood and sexual contact (horizontal transmission), while 
children can become infected through peri- or neonatal exposure and 
horizontal transmission, the predominant mode of infection in African infants 
and young children (3-5). Peri- and neonatal transmitted HBV is rarely cleared 
and up to 90% of neonatal infected children become chronically infected (2, 6). 
In contrast, the virus is usually cleared by the adult immune system and less 
than 5% of infected adults develop persistent infections (7). HBV infection may 
result in acute and chronic liver disease, cirrhosis and hepatocellular carcinoma 
(HCC) (1, 2). These diseases have a high risk of developing in chronically 
infected patients and claim approximately 500 000 to 1.2 million lives per 
annum, therefore, developing a cure is a top priority (1). Effective vaccines 
against HBV infection have been developed and have reduced the incidence 
of chronic HBV infections and HCC in areas where HBV immunisation has been 
introduced (2, 8). However, the vaccines do not cure existing chronic HBV 
infections and are difficult to access in far removed and secluded areas where 
HBV infection is unchecked (2, 8-12). Current HBV therapeutics manage HBV 
infections, but as a result of persistent HBV covalently closed circular DNA 
(cccDNA) are unable to clear the virus (13). The HBV cccDNA acts as an 
essential transcriptional template for viral replication, persists as a replication 
intermediate and needs to be addressed to facilitate viral clearance (14). DNA 
sequence specific nucleases such as transcription activator-like effector 
nucleases (TALENs) have recently shown promise as antiviral agents that can 
target, modify and disrupt the viral cccDNA (15). These TALENs introduce 
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double stranded breaks (DSBs), which are repaired by the non-homologous 
end joining (NHEJ) DNA repair pathway. These DSBs can also be repaired by 
the homology directed repair (HDR) pathway if homologous donor template 
strands are present (16). It should therefore be possible to exploit the HDR 
pathway by introducing an artificial donor template strand that contains an anti-
viral sequence. HDR should integrate the artificial sequence into the HBV 
cccDNA and result in disruption of the viral genome and subsequent 
replication. 
 
 
1.2 HBV life cycle 
 
The current knowledge of HBV structure and life cycle is perused to identify 
potential target genome sites for TALEN cleavage and HDR-mediated 
integration of an anti-viral sequence. 
HBV is a non-cytopathic virus that belongs to the Hepadnaviridae family of the 
Orthohepadnavirus genus. It has two DNA arrangements: partially double-
stranded relaxed circular DNA (rcDNA) in the virions and cccDNA, which only 
exists inside the host. The virus has a limited host range and an affinity for 
hepatocytes (2, 17). The viral core, containing the rcDNA and viral polymerase, 
is encapsulated by an outer lipid envelope that consists of viral surface 
antigens and host-derived lipids (2) (Figure 1.1). The envelope proteins are 
essential for cell binding and entry into the susceptible hepatocytes (18, 19). 
During infection the virion binds to low-affinity receptors (heparan sulphate 
proteoglycans). This is followed by viral entry through endocytosis mediated by 
specific interaction between HBV and sodium taurocholate co-transporting 
polypeptide (NTCP), a recently described functional receptor for HBV (2, 20-
22). The lipid envelope is dissolved and the nucleocapsid particles are 
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transported to the nuclear membrane by chaperone proteins, where they are 
disassembled by host nuclear pore complexes (NPC) (Figure 1.1). After 
disassembly of the nucleocapsid particles the rcDNA is released into the cell 
nucleus and undergoes DNA repair by host factors to form cccDNA (2, 17, 23). 
This cccDNA acts as an essential transcriptional template for viral replication 
and does not have to be integrated into the host genome (14, 24). The pool of 
transcriptional templates within the hepatocyte is amplified by transcriptional 
regulation of cccDNA. These cccDNA templates encode pre-genomic RNA 
(pgRNA) and four viral subgenomic mRNAs (sgRNAs) required for virion 
assembly, and are transcribed by the host RNA polymerase II (17, 25). Viral 
mRNAs are translated and progeny virion particles are produced. HBV core 
antigens (HBcAg) self-assemble and form nucleocapsid particles within the 
host cytoplasm. During virion assembly the pgRNA and viral polymerase are 
packaged in the core capsid (Figure 1.1). The viral polymerase reverse 
transcribes the pgRNA, a replication intermediate, to form rcDNA within the 
nucleocapsid. Once reverse transcription is complete, the virion acquires an 
outer envelope that is completed by the Golgi apparatus and mature virions 
with complete envelopes are then secreted from the cell. The nucleocapsid 
enclosing the rcDNA can also be redirected to the cell nucleus to increase the 
cccDNA pool of the host cell. The cccDNA in this pool can persist as HBV 
replication intermediates in the hepatocyte during disease progression (2). The 
epigenetic regulation of cccDNA through the acetylation status of coupled 
histones in DNA allows it to remain dormant in the hepatocyte nucleus for 
months or years (26, 27). This allows the virus to evade the host immune 
response and reactivate viral replication, resulting in latent or occult viral 
infection (reviewed by (27-30)). 
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1.3 HBV genome structure and viral proteins 
 
The HBV genome expresses viral proteins that are important for viral 
replication and virion assembly. Therefore, knowledge of the genome structure, 
the viral proteins, and their roles in HBV replication is essential for development 
of effective anti-HBV therapies that target these latent HBV cccDNA reservoirs. 
The HBV partially double-stranded DNA genome has a length of approximately 
3.2 kilobases (kb) and is repaired upon entry into the cell nucleus to form 
cccDNA. The cccDNA consists of four open reading frames (ORFs) that 
transcribe the pgRNA and three sgRNAs (reviewed by (25, 31, 32)) (Figure 
1.2). The pgRNA is 3.5 kb long and contains the ORFs for translation of the 
viral polymerase and precore/core proteins. The Golgi apparatus processes 
the precore protein to form hepatitis e antigen (HBeAg), which is an important 
regulator of the innate and adaptive immune responses and down regulates 
interferon (IFN)-γ expression by natural killer (NK) cells (33, 34). HBeAg and 
the precore protein are not required for HBV replication, but are important for 
establishment of persistent viral infection (35, 36). Hepatitis B core antigens 
(HBcAgs) are the translational products of the second initiation codon of the 
precore/core ORF and are essential for the formation of the viral nucleocapsid. 
HBV polymerase initiates reverse transcription of pgRNA to produce rcDNA, 
which contains an incomplete positive DNA strand that is capped by a short 
RNA oligomer at the 5’ end (37, 38). The negative rcDNA strand contains a gap 
region that is flanked by Direct Repeat 1 and 2 (DR1 and 2) (Figure 1.2). DR1 
and 2 are repetitive sequences on both the positive and negative DNA strands 
that function as recognition sites during viral replication (37, 39, 40). The 
surface ORF encodes the major surface proteins and contains two upstream 
reading frames, pre-S1 and pre-S2, which encode the large and middle surface 
proteins respectively. The major, large and middle surface proteins are 
essential for the formation of the new viral envelope and are immunologically 
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identified as hepatitis B surface antigens (HBsAgs), which are indicators of 
HBV infection. Transactivator hepatitis B X protein (HBx) is encoded by the 
HBx ORF. Its complete role in regulation of HBV replication remains elusive, 
but recent studies indicate that HBx has an important role in stimulating HBV 
transcription and replication in the host cell by regulating transcription of cellular 
genes (41-44).  
However, there are currently 10 different HBV genotypes (A-J). The genome 
structure and HBV protein expression vary for each genotype, making 
development of anti-HBV treatments challenging (45-49). Current treatments 
are not effective for all HBV genotypes, necessitating development of novel 
treatments that target all HBV genotypes. 
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Figure 1.1: Hepatitis B virus life cycle. The virus enters the host cell through endocytosis mediated by specific interaction between HBV 
and sodium taurocholate co-transporting polypeptide (NTCP). The partially double stranded DNA genome of the virus is released from the 
viral capsid upon entry into the host cell. The genome is translocated to the cell nucleus and repaired to form cccDNA. pgRNA and various 
subgenomic mRNAs are transcribed from the cccDNA. Proteins required for new virion assembly are translated from the mRNAs and the 
pgRNA is translated into polymerase. The pgRNA is reverse transcribed to form rcDNA within the new viral capsid and the viral genome is 
either surrounded by surface proteins and buds from the cell or it can re-enter the cell nucleus to produce more viral cccDNA. (Diagram used 
with permission from Dr A. Ely, Antiviral Gene Therapy Research Unit (AGTRU), University of the Witwatersrand, South Africa)
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Figure 1.2: Hepatitis B Virus genome organization. The centre of the circular genome map 
is a schematic representation of the HBV rcDNA. The viral genome consists of precore/core, 
pre-S1, pre-S2/S and HBx ORFs (shown by arrows immediately surrounding the HBV genome 
at the centre of the circular genome map). Viral transcripts are represented by the four outer 
arrows and transcription initiation sites are represented by various objects. HBV polymerase 
initiates reverse transcription of pgRNA to produce rcDNA with a positive strand that is only 
partially synthesized. DR1 and DR2 flank the gap region in the negative strand and function as 
recognition sites during viral replication (31). 
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1.4 Host immune response 
 
The adult immune response effectively clears most acute HBV infections (7). 
As a result, multiple anti-HBV treatments that induce, amplify or mimic the 
immune response have been developed (13, 50-54). However, these 
treatments are unable to clear the virus and further investigation of the immune 
response could lead to novel HBV treatments. 
Liver disease and viral clearance after HBV infection occur as a result of the 
host immune response to viral agents (55). The immune response involves 
CD4+ T-helper cells and cytotoxic CD8+ T-cells, production of type 1 interferon 
α/β (IFN-α/β), and activation of natural killer (NK) cells. The NK cells are 
activated during the innate immune response and are able to eliminate infected 
cells by direct cytolysis and production of inflammatory cytokines, such as IFN-
γ and tumour necrosis factor α (TNF-α). These cytokines are important in the 
cytotoxic CD8+ T-cell response and containment of the virus during the early 
phase of infection (33, 34). The innate immune system responds to HBV 
infection by eliciting strong human leukocyte antigen (HLA) class I and II 
restricted T cell responses. The antigens stimulate increased production of T-
helper cells, which in turn stimulate the antibody-producing B-cells to produce 
antibodies to HBV antigens (56). A polyclonal cytotoxic T lymphocyte (CTL) 
response to the multiple HBV encoded antigens is observed in patients with 
acute viral infection who successfully clear the virus. The T-cell response is 
weak or absent in patients that do not clear the virus and become chronically 
infected, confirming the importance of the CTL for viral clearance (3, 57, 58). 
The IFN-γ produced by the NK and cytotoxic CD8+ cells lyses infected 
hepatocytes and is the primary cause of HBV associated liver injury (59). The 
degree of liver injury and the outcome of acute HBV infection are determined 
by the magnitude of the immune response to the HBV related antigens (60). 
However, IFN-γ can also suppress viral replication without damaging 
hepatocytes (61, 62). This ability to suppress viral replication without damaging 
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the liver cells and the efficiency of the host immune response to clear the virus 
resulted in development of multiple HBV treatments that exploit these 
attributes. 
 
 
1.5 Managing HBV infections 
 
 Current HBV treatments 
 
Current HBV vaccines cause the host immune response to produce antibodies 
against an inactive form of the virus (9-12). These vaccines are very effective 
in preventing HBV infection, but do not cure existing HBV infections (25). 
Therefore, developing novel treatment strategies to manage chronic HBV 
remains an important medical objective. Current therapeutics for HBV include 
immunomodulators and nucleotide/nucleoside analogues (13, 63, 64). The 
ability of IFN to induce the host immune response against HBV encouraged 
researchers to develop immunomodulators that boost the host response. 
Current immunomodulators include IFN-α-2b and pegylated interferon 
(pegIFN) α-2a. These immunomodulators function as anti-viral agents and aid 
in clearing the virus by boosting the host T-cell response (52, 53). HBeAg, an 
important regulator of the innate and adaptive immune responses, inhibits IFN-
γ expression. Therefore, changes in HBeAg levels may predict HBV response 
to IFN treatment (35, 36). IFN-α has been used as treatment for both HBeAg 
positive and negative chronic hepatitis B and has been successful in reducing 
HBV replication. However, IFN treatment is only effective in ±35% of HBeAg 
positive patients and approximately 60% of patients did not respond to repeat 
treatment (65). IFN induced development of antibodies against HBeAg in 85-
90% of patients, while delayed antibody formation occurred after 1-2 years in 
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10-15% of patients (66, 67). IFN therapy was successful in 60-90% of treated 
HBeAg negative patients. However, more than half of these patients relapsed 
post-therapy, resulting in a low sustained response. Retreatment resulted in a 
20-40% response rate (68, 69). PegIFN has a higher combined response and 
resulted in antibody development in approximately 31% of patients (70). This 
data indicates that chronic HBV can be treated successfully with IFN therapy, 
but the effectiveness of the treatment is low and successful alternatives are 
required (25, 50). Lamivudine, Entecavir, Adefovir dipivoxil, Telbivudine and 
Tenofovir are nucleotide/nucleoside analogues that show anti-HBV efficacy 
(13, 50, 51, 54). These analogues are chemically synthesised and can be 
incorporated into HBV DNA during DNA polymerisation, facilitated by their 
structural similarity to the nucleosides (56). The analogues disrupt viral 
replication by inhibiting viral reverse transcriptase and polymerase. Lamivudine 
is equally effective in HBeAg-positive and HBeAg-negative carriers. It inhibits 
establishment of new cccDNA, reduces HBV DNA levels, and reverses liver 
damage (71, 72). However, a major drawback of Lamivudine usage is the 
emergence of drug-resistant strains of HBV after treatment. Mutations within 
the tyrosine-methionine-aspartate-aspartate (YMDD) motifs in the catalytic site 
of the HBV polymerase have been shown to confer Lamivudine resistance and 
reactivation of HBV (73). Adefovir dipivoxil and Entecavir have achieved 
increased efficacy against HBV and both agents inhibit the emergence of 
mutant viral strains (50, 63, 74). Telbivudine and Tenofivir have been available 
since 2006 and 2008 respectively. These agents exhibit activity against both 
HBV and the human immunodeficiency virus (HIV) and are used to treat 
HBV/HIV co-infection (75).  
However, these existing therapeutics are unable to eradicate the established 
HBV cccDNA reservoirs and continuous treatment is required to prevent future 
viral reactivation and emergence of mutated viral strains. Therefore, HBV 
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cccDNA remains a major hurdle for chronic HBV treatment and novel methods 
are required to eliminate these cccDNA reservoirs. 
 
 
1.6 Engineered site-specific endonucleases 
 
Manipulation of DNA and RNA shows promise as antiviral agents against HBV, 
allowing targeting of both pre- and post-transcriptional events in the viral life 
cycle (63, 76-78). As a result, various technologies, such as antisense 
compounds, aptamers, RNA interference (RNAi) effectors, ribozymes and 
designer endonucleases, have been developed for this purpose. These 
technologies manipulate HBV DNA and RNA and have shown promise for the 
treatment of various persistent infectious diseases (76, 79-84). 
Precise, predictable alteration of a target DNA sequence is required for 
genome manipulation (77, 78, 85). Advances in engineering targeted 
nucleases that contain programmable, site-specific DNA binding domains have 
facilitated significant progress in development of technologies that can be used 
to target specific sequences and further development of these technologies 
remains top priority (86). Meganucleases, RNA-guided endonucleases 
(RGENs), zinc finger nucleases (ZFNs) and transcription activator-like effector 
nucleases (TALENs) are four different designer nucleases currently used 
specifically for DNA engineering (87). 
Meganucleases and RNA-guided endonucleases (RGENs) both have natural 
endonuclease activity. Meganucleases were first identified in mobile genetic 
elements of yeast and are engineered versions of naturally occurring DNA 
targeting restriction enzymes with extended DNA recognition sequences that 
bind a specific 12-40 bp DNA target sequence (87). The enzymes cleave the 
DNA target, creating a double stranded break (DSB) which triggers 
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homologous recombination events (88, 89). Artificially designed 
meganucleases have been successful in targeting specific target DNA 
sequences (90-92). However, the DNA recognition and cleavage function of 
meganucleases are intertwined in a single domain, making the engineering of 
these enzymes a challenge for most researchers (93). 
RGEN is an alternative method that has recently shown promise for genome 
engineering applications. RGENs are based on a bacterial clustered regular 
interspaced short palindromic repeats (CRISPR) defence system which uses 
RNA-guided endonuclease activity to disable invading DNA. In this system 
CRISPR RNA (crRNA), which contains protospacers, hybridises with 
transactivating crRNA (tracrRNA) and forms a complex with CRISPR 
associated protein 9 (Cas9). The protospacer-encoded region of the crRNA 
then directs Cas9 to a complimentary DNA target sequence adjacent to a 
protospacer adjacent motif (PAM), allowing Cas9 to facilitate DNA cleavage 
(87, 94, 95). CRISPR is an important new approach for generating RNA-guided 
nucleases with customizable specificities. CRISPR technology has potential for 
RGEN-mediated site-directed cleavage and has recently been successful in 
multiple genome engineering projects (79, 87, 96-98). However, these designer 
nucleases have only recently been described and further analysis of the 
CRISPR-Cas9 system activity and genome-wide specificities is required (87, 
99). 
Zinc finger nucleases (ZFNs) are a more established genome engineering 
technology. Zinc finger (ZF) domains are capable of recognising nucleotide 
triplets and have been studied in-depth (85, 100). The modular structure of the 
ZF motif permits several domains to be joined in series. These arrays are 
capable of targeting various DNA sequences upstream of genes and can be 
fused with transcriptional activation or repressor proteins to form gene 
regulators (101). ZF arrays have also been fused to a non-specific FokI 
catalytic domain to generate ZF nucleases (ZFNs) (85, 100). A ZFN monomer 
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usually consists of 3-6 ZF motifs and targets DNA sequences that are 9-18 bp 
long. The FokI domains of two ZFN monomers dimerise to form a functional 
endonuclease that results in cleavage of both the positive and negative DNA 
strands (100). Designer ZFNs have been used in multiple genome engineering 
projects that involved targeted DNA mutations and specific editing of complex 
genomes in a variety of cells and organisms (78, 79, 85, 100-109). However, 
robust construction of ZFNs has proven difficult. Neighbouring ZFs in ZFNs 
affect the specificity of the ZFN and therefore a specific context dependent 
subunit arrangement is required to effectively bind DNA (85, 110-114). This 
warrants investigation into technologies, such as TALENs, that require less or 
no context specificity. 
Transcription activator like effectors (TALEs) also recognise specific DNA 
sequences (115, 116). TALEs were first discovered in Xanthomonas, a 
pathogenic plant bacteria. The bacterial type III secretion system injects the 
TALEs into plant cells. The injected TALEs are then transported to the cell 
nucleus, where they bind to the target DNA sequence and activate downstream 
gene expression (110, 117, 118). TALEs consist of individual monomers, which 
consist of 33-35 amino acid repeat domains that recognise a single DNA base 
pair (Figure 1.3) (115, 116). Most TALEs consist of 13 to 28 repeats and the 
last repeat is truncated at 20 amino acids (110, 119). Polymorphisms are 
formed by the hypervariable amino acid residues 12 and 13, which are known 
as the repeat variable diresidues (RVDs). These RVDs show specific 
preferences for different DNA nucleotides. The NG, HD, NI and NN RVD 
domains show affinity for thymidine (T), cytosine (C), adenine (A) and guanine 
(G) respectively (115, 116, 120). These repeats can be added in tandem to 
target a specific DNA sequence. However, it has recently been reported that 
engineered TALE DNA binding domains are affected by the 5-methylated 
cytosine (5mC), an epigenetic modification, in their target DNA sequence (121, 
122). 5mC is very common in different cell types and genomic kingdoms. The 
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negative impact that 5mC has on dTALE activity is potentially a major drawback 
to the use of TALE-based technologies considering how ubiquitous this 
modification is. However, Valton et al. demonstrated that substituting the 
sensitive-to-cytosine-methylation HD domain with a methylation insensitive N* 
domain efficiently accommodates 5mC in the target sequence and negates the 
negative impact on TALE activity (122). There are other known RVD domains 
that also associate more specifically with certain DNA bases and more than 
one type of nucleotide, but TALEs with these alternative RVD domains tend to 
exhibit decreased activity (116, 123). The number and composition of TALE 
DNA-binding domains determine the DNA sequence that the TALE array will 
bind. User defined DNA sequences can be targeted by designer TALEs that 
are assembled by joining the TALE repeats in a specific order (15, 86, 124, 
125). 
The designer TALEs can be fused to different effector domains to create 
nucleases, repressors and transcriptional activators. TALE nucleases 
(TALENs) are TALEs fused with a FokI catalytic domain (Figure 1.3). These 
TALENs are designed in pairs (a left and right TALEN pair) that target 
complimentary DNA targets separated by a 14-15 bp spacer region (110, 126). 
TALEN specificity is of utmost importance to prevent off-target effects, and may 
be affected by various factors. The composition and number of repeats in 
TALENs affect TALEN specificity, as RVDs differ in their stringency for specific 
nucleotide preferences (110, 127). The length of the spacer region between 
two TALENs also affects TALEN specificity (85, 124, 127). However, in contrast 
to ZFNs, TALEN specificity is not affected by the context of the TALE repeats 
(116).  
TALENs are effective and have successfully been used in multiple genome 
engineering projects (79, 99, 124, 127-131). Recently Reyon et al. 
demonstrated that TALENs have good efficacy against a wide variety of targets 
within the human genome and by applying careful design rules it is possible to 
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develop TALENs which target essentially any DNA sequence in the human 
genome (132). These results were supported by findings from Mussolino et al., 
who showed that TALENs are able to discriminate between highly similar 
sequences (CCR5 and CCR3) (85). Early studies indicate that TALENs result 
in little or no off-target mutagenesis (85, 127, 133, 134). However, these 
studies are limited in scope as they only analyse predicted off-target sites (135, 
136). As a result, recent studies sequenced the complete genome of human 
induced pluripotent stem cells (hiPSCs). These studies demonstrated that gene 
correction by TALENs in single cell clones exhibits a low level of sequence 
variation and few off-target effects. The observed single-nucleotide variants 
(SNVs) were not within the potential off-target regions. Results suggest that 
TALENs induce rare SNVs in a non-random manner, or that the mutations were 
not direct results of off-target TALEN activities, but were randomly accumulated 
during regular cell expansion (135-137). Therefore, TALENs provide highly 
specific and efficient genome-editing tools and the incidence of off-target 
effects is not a significant concern for disease modelling and genome-editing 
applications (135, 137). 
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Figure 1.3: TALEN pairs that introduce DNA double stranded breaks. Each TALEN 
consists of a number of RVD-containing TALE repeats and a FokI catalytic domain which is 
separated from the TALE repeats by a spacer region. FokI acts as a dimer, thus requiring two 
FokI catalytic domains (left and right TALENs) to cleave the DNA strand. 
 
 
 
 
 
 
 
 
 
Chapter 1 
17 
 
1.7 DNA repair pathways 
 
Dimerisation of the TALEN FokI domains introduces site specific DNA double 
stranded breaks (DSBs) (16). These DSBs result in DNA transcription, 
replication, and segregation complications and can lead to a rise in 
chromosomal instability if they are not correctly processed and repaired. DSBs 
induce the DNA repair response, which has two primary components in 
eukaryotic cells: (1) non-homologous end joining (NHEJ) and (2) homology 
directed repair (HDR) (110, 138-140). Both NHEJ and HDR may be 
manipulated to change the underlying DNA sequence by either inclusion or 
deletion of specific base pairs. Both repair pathways have been successfully 
exploited to introduce targeted genome alterations in multiple organisms and 
cell types, and present a novel mechanism by which to influence or edit an 
organism’s genome (78, 111, 141). 
 
 Non-homologous end joining 
 
NHEJ is the predominant repair mechanism in mammalian cells and operates 
at all stages of the mammalian cell cycle (Figure 1.4) (138, 142). The repair 
mechanism uses micro homologies to stabilise the NHEJ complex, but does 
not require sequence homologies or an intact homologous DNA template to 
ligate DNA ends and as a result produces junctions that can vary in sequence 
composition (138, 143-146). NHEJ may be error prone and can introduce 
deletions or short insertions of foreign DNA that can result in harmful frameshift 
mutations and gene knockouts (110, 111, 140, 147, 148). However, NHEJ is 
efficient in restoring the phosphodiester backbone and structural integrity of the 
DNA strand (140). Bloom et al. demonstrated that NHEJ can be exploited to 
introduce specific HBV genome alterations that are harmful to the virus (15). 
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 Homology-directed repair 
 
Homology directed repair (HDR) is an accurate DNA repair mechanism used 
by cells to repair DSBs (16, 143, 149-151). The mechanism is crucial for 
accurate genome duplication and preservation of the genome. HDR is induced 
if a double-stranded homologous DNA donor template is present at a DSB site. 
This undamaged homologous DNA sequence is used as a template for new 
DNA synthesis, allowing accurate repair of the DSB (139). There are four main 
HDR models: 1) Single strand annealing (SSA), 2) Break induced replication 
(BIR), 3) Double-strand break repair (DSBR) and 4) Synthesis-dependent 
strand annealing (SDSA). The SSA model states that a DSB flanked by 
homologous direct repeats is repaired by a deletion process. SSA is 
independent of strand invasion and does not require homologous donor 
template strands for DNA repair. However, DNA repair results in deletion of the 
sequences between the direct repeats and one of the flanking direct repeats 
(152, 153). BIR is a single ended invasion process that occurs if a single 
resected DSB end is present (154, 155). The single-strand tail invades a 
homologous DNA template and information is copied from the invaded 
sequence by DNA synthesis. BIR restores the integrity of the chromosome, but 
can also result in loss of heterozygosity of genetic information distal to the DSB 
(156). 
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Figure 1.4: Double stranded break repair pathways. The imprecise NHEJ repair pathway 
can produce indels (insertions and/or deletions) of various lengths. The SDSA model of HDR 
uses a donor strand (from a sister chromatid or artificial sequence) as a template. The single-
stranded chromosome end invades the homologous sequences of the donor. A D-loop is 
formed and is trailed by the newly synthesised single-stranded DNA. The two newly 
synthesised stretches of DNA can leave the D-loops once they overlap. The D-loops collapse 
once the new synthesised strands leave and the two overlapping strands anneal to each other 
and use each other as templates in order to restore the DNA integrity. The repaired DNA now 
contains the donor-specified transgene/artificial sequence. 
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During DSBR and SDSA the DSB undergoes nucleolytic processing, resulting 
in single strand DSB tails with 3’-OH ends. The single strand DNA (ssDNA) 
ends become the substrates for HDR protein machinery to execute invasion of 
the donor strand. Recombinases bind to the ssDNA end and form a helical 
filament that searches for homology through random collisions between the 
nucleoprotein filament and DNA sequences (16, 157, 158).  Homologous 
sequence strand invasion occurs after a successful homology search and 
results in formation of a nascent D-loop intermediate, during which the 3’ end 
of the invading strand is extended by DNA polymerase. During DSBR the 
second DSB end is annealed to the extended D-loop, thereby capturing it and 
resulting in formation of two crossed strands (Holliday junctions (HJs)). The 
HJs are resolved by a specialised endonuclease to produce crossover or non-
crossover products. Most mitotic DSB repairs are not associated with 
crossovers (16, 159). 
SDSA is the predominant pathway in mitotic repair if a second DSB end is 
present (Figure 1.4) (reviewed by Shinohara and Ogawa (160)). With SDSA 
the migration D-loop does not capture the second DSB end as in DSBR. The 
D-loop unwinds and the invading strand is displaced after initial DSB-end 
resection, strand invasion, and DNA repair synthesis. The displaced strand 
then anneals to the complementary ssDNA strand that is associated with the 
opposite resected DSB end (144, 161). Gap-filling DNA synthesis and strand 
annealing occur and finish the replication process. No crossover products are 
formed as HJ formation is blocked by HDR proteins in vitro, thus reducing 
potential genomic rearrangements during the repair process (162). This results 
in bias towards the SDSA mechanism, which can be exploited to introduce 
specific genomic alterations. 
HDR can be co-opted to facilitate the integration of specific sequences at 
targeted genomic loci. This is achieved by developing donor sequences with 
high sequence homology, either flanking a portion of non-homologous DNA, or 
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with a single base pair change that can facilitate gene disruption or 
augmentation. Use of HDR as a genome engineering tool is becoming more 
frequent. Research groups recently demonstrated that ZFN-based nicking 
enzymes can be used to insert DNA sequences at predetermined sites in 
selected genomes (163, 164). Wang et al. utilised engineered ZFNs 
(ZFNickases) that introduce site-specific DNA single-strand breaks (SSBs) or 
nicks in the endogenous CCR5 locus in both transformed and primary human 
cell lines (164). Researchers stimulated gene addition and correction by 
introducing a homologous donor template and succeeded in inserting an 
artificial DNA sequence at the AAVSI locus. Ramirez et al. also demonstrated 
that ZFNickases efficiently generate DNA SSBs in vitro. The SSBs and addition 
of donor templates stimulated HDR, and they were able to successfully repair 
a chromosomal enhanced green fluorescent protein (EGFP) sequence in 
U2OS-based reporter cells by inserting artificial DNA sequences at the nicking 
site (163). Both groups reported reduced levels of NHEJ-mediated 
mutagenesis. Bedell et al. demonstrated that their designer TALENs efficiently 
induce locus-specific DSBs in zebrafish somatic and germline tissue. The 
researchers stimulated HDR in zebrafish by introducing TALEN-mediated 
DSBs and single stranded donor template strands, and were able to precisely 
modify sequences at selected locations in the zebrafish genome. They also 
inserted a custom EcoRV site and a modified loxP sequence into zebrafish 
somatic tissue in vivo (165). Osborn et al. used HDR to repair the type VII 
collagen gene defects in cells with recessive dystrophic epidermolysis bullosa 
(166). The research group generated TALEN-induced site-specific DSBs which 
stimulated HDR from an exogenous donor template and resulted in gene 
mutation correction (COL7A1) in primary fibroblasts. Wang et al. were able to 
edit the mouse Y chromosome in mouse embryonic stem cells. They created 
TALEN-induced DSBs at the Sry and Uty loci and introduced a donor template 
that contained a puromycin selection marker and a promoterless GFP flanked 
by 700 bp 5’ and 385 bp 3’ homologous regions. Introduction of the donor 
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template stimulated HDR and subsequent analysis confirmed that the donor 
constructs were successfully inserted at the target sites (167). The collective 
results from these research groups indicate that targeting the HBV genome 
with designer TALENs and introducing homologous donor templates to induce 
HDR is a promising prospect for developing anti-HBV therapy. It follows that 
possible anti-HBV sequences, such as RNA interference effecters, can be 
incorporated into these homologous donor templates and needs to be 
investigated.  
 
 
1.8 RNA interference pathway 
 
Alternative gene therapies, such as RNA interference, have been shown to 
have significant potential. Therefore, it should be possible to disrupt viral 
activity by targeting selected viral genome targets with both RNA interference 
effecters and designer endonucleases. 
The RNA interference pathway (RNAi) forms part of the post-transcriptional 
mechanism of HBV replication and studies demonstrated that RNAi effecters 
have potential for antiviral gene therapies that target chronic HBV (168, 169). 
RNAi induces posttranscriptional gene silencing by degradation or translational 
suppression of a target messenger RNA (mRNA) (170). RNA polymerase II 
transcripts express primary microRNAs (pri-miRs) which are cleaved to 
produce precursor microRNAs (pre-miR) (Figure 1.5) (171). Pre-miR is 
exported to the cytoplasm and cleaved to form a miR/anti-miR duplex (172). 
This duplex is loaded onto the RNA-induced silencing complex (RISC) which 
guides the miR to the target mRNA(168). The miR/RISC complex then either 
inhibits mRNA translation or cleaves the mRNA (168, 173). Polymerase II 
expression cassettes achieve tissue-specific and inducible expression of RNAi 
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effecters (168, 174, 175). Ely et al. demonstrated that modular cassettes 
expressed from Poll II promoters should be advantageous for simultaneous 
silencing of multiple different genome sites (169). The researchers targeted 
three different HBV viral genome sites with primary pri-miR-31-derived shuttles 
encoded by modular trimeric anti-HBV Pol II cassettes. They then 
demonstrated that their transcribed pri-miR trimers generated the intended 
guide strands and effectively silenced the selected targets. HBV replication was 
inhibited both in cell culture and in vivo, without disrupting the endogenous miR 
function or inducing an IFN response. We propose that this pri-miR cassette 
can be incorporated into the homologous donor template strands utilised by 
HDR. HDR should integrate the pri-miR cassette into a selected target 
sequence to facilitate pri-miR expression and subsequent inhibition of HBV 
replication. 
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Figure 1.5: MicroRNA biogenesis in the RNAi pathway. Pri-miRNA is transcribed in the cell 
nucleus and is processed by Drosha into pre-miRNA. An Exportin-5 mediated pathway exports 
the pre-miRNA to the cytoplasm, where it is processed by Dicer into a miRNA duplex. The 
miRNA duplex unwinds when it associates with RISC and guides the complex to the target 
mRNA for translational repression or endonucleolytic cleavage (Diagram adapted with 
permission from Dr A. Ely, Antiviral Gene Therapy Research Unit (AGTRU), University of the 
Witwatersrand, South Africa). 
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1.9 Designer endonucleases targeting HBV cccDNA 
 
As discussed in 1.4.2, current therapeutics rely on post-transcriptional 
mechanisms to inhibit HBV replication and do not target HBV cccDNA. HBV 
cccDNA drives HBV transcription and progeny virus production and is, 
therefore, a promising target for genome engineering applications and 
alternative HBV therapies. Zimmerman et al. reduced viral RNA levels by 
targeting the enhancer region of HBV cccDNA with ZFNs in a duck hepatitis B 
virus (DHBV) model. They transfected longhorn male hepatoma cells with 
DHBV replicating plasmids and ZFNs. Transfection with the ZFNs resulted in 
significant reduction in viral RNA levels, HBV protein concentration and 
intracellular viral particles, and a subsequent decrease in viral product 
production and progeny virus genomes (176). Another research group used 
designer TALENs to target conserved regions of viral genomic DNA in different 
HBV genotypes (177). Transfection of Huh7 cells with monomeric full length 
HBV DNA and TALENs resulted in significant reduction of HBcAg, HBeAg, 
HBsAg and pgRNA. The TALENs also resulted in misrepaired cccDNAs and a 
decrease in cccDNA levels, while no apparent cytotoxic effects were noted. In 
addition, Chen et al. demonstrated anti-HBV activity via TALENs in a 
hydrodynamic, injection-based mouse model. They also tested a TALEN and 
IFN-α combination treatment, which successfully restored the suppressed IFN-
stimulated response against HBV (177). In another study, Bloom et al. 
successfully designed four TALENs that target four different HBV specific sites 
within the viral genome (15). TALENs targeting the HBV surface and core 
ORFs (S and C TALENs) resulted in sequence disruption at the target sites 
and a decrease in viral replication markers (HBsAg). Transfecting HepG2.2.15 
cells thrice with S TALENs resulted in mutation of approximately 35% of the 
cccDNA. The researchers also demonstrated TALEN-mediated reduction of 
HBV replication markers in a murine hydrodynamic injection model of HBV 
replication. In this model the surface and core ORF target sites were mutated 
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and no in vivo cytotoxic effects were reported. The results from these research 
groups confirm that designer endonucleases can be used to successfully target 
HBV cccDNA and induce site-directed mutagenesis, thereby permanently 
disabling viral replication (15, 176, 177). The TALEN-mediated DSBs in 
cccDNA can also stimulate HDR if a homologous donor template is introduced. 
It follows that HDR could then integrate an artificial donor sequence at the 
cccDNA target site. 
 
 
1.10 Experimental design and rationale 
 
We propose that homology directed disruption of the HBV cccDNA using 
designer TALENs and donor template strands with pri-miR cassettes will result 
in improved HBV inactivation in an HBV replication model in cultured cells. 
Designer TALENs can be utilised to induce DNA DSBs at specific HBV cccDNA 
genome targets, resulting in both NHEJ and HDR. NHEJ has been shown to 
introduce indels at specific target sites and resulted in significant inactivation of 
HBV replication by disrupting viral transcription processes (15). HDR can be 
exploited to insert a pri-miR cassette at the target sites, as pri-miR expression 
has been shown to disrupt HBV replication without affecting the rest of the HBV 
genome (Figure 1.6) (78, 163, 165, 178). Ely et al. demonstrated pri-miR-
31/5/8/9 cassettes that result in efficient disruption of HBV replication(169). 
Therefore, combining TALENs and pri-miR-31/5/8/9 should result in improved 
HBV disruption, as disruption will be caused by pri-miR expression as well as 
DSB-mediated NHEJ and HDR. Double stranded DNA strands are effective 
donor templates for HDR-mediated genome editing (124, 128). Therefore, an 
exogenous pri-miR sequence can be integrated into artificial dsDNA strands 
that are homologous to the TALEN target sites. These custom DNA sequences 
then act as donor templates for HDR of the TALEN-induced DSBs. In our 
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project designer TALENs were used to create DSBs at HBV core and surface 
target sites, which result in site-directed mutagenesis of HBV DNA (15). These 
TALEN-mediated DSBs should also result in HDR-mediated disruption of HBV 
DNA if a donor template is introduced. Donor templates with longer flanking 
homologous sequence lengths (400-800 bp) result in increased target 
efficiency and HDR frequency (167). However, it has been suggested that 
shorter homologous sequence lengths may also result in optimal HDR in some 
cell types, therefore, the optimum homologous sequence length has to be 
determined (127, 179). Our first objective was to construct linear donor 
template strands which contain a promoter-less pri-miR-31/5/8/9 cassette 
flanked by sequences that vary in length and are homologous to HBV core and 
surface target sites (169). The second objective was to analyse and optimise 
the integration of the donor sequence at the TALEN-mediated DSBs. The linear 
artificial donor template strands and designer TALENs are co-introduced to the 
cell cytoplasm and the viral core and surface target sites should be disrupted 
by TALEN-mediated NHEJ and HDR. HDR should incorporate the pri-miR-
31/5/8/9 cassette at the target sites where an HBV promoter will drive pri-miR 
expression (Figure 1.6). Pri-miR will then be processed into mRNA, which 
forms a complex with RISC. This complex silences HBx and should result in 
significant disruption of HBV replication. Therefore, our proposed method 
targets HBV cccDNA and viral replication in a synergistic manner and should 
result in decreased viral replication and possible elimination of the viral cccDNA 
reservoirs. 
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Figure 1.6: Insertion of the donor sequence at the core and surface cccDNA target sites. 
Two TALENs bind to their respective target sites, allowing the FokI catalytic sites to dimerise 
and cleave the double stranded DNA, thus introducing a DSB and activating the DNA repair 
pathways. Donor template strands containing three stop codons and a pri-miR-31/5/8/9 
cassette flanked by sequences that are homologous to the TALEN target sites are introduced. 
The HDR pathway uses the donor strands as repair templates and integrates the artificial 
sequence into the cccDNA. Successful integration should then result in target site disruption 
and HBV promoter driven pri-miR expression, which should disrupt HBV replication and 
decrease HBsAg expression. 
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2. Materials and methods 
 
2.1 Plasmids 
 
 pCH-9/3091  
 
pCH-9/3091 is a longer than genome length HBV equivalent developed by 
Nassal et al. to simulate HBV replication in cell culture (180). This plasmid is 
capable of replicating in vitro and encodes the wild-type HBV subtype D 
genome, using a cytomegalovirus (CMV) immediate early promoter to drive 
viral protein expression. The circular structure of the HBV genome is mimicked 
by including two terminal repeats. RNA produced from the pCH-9/3091 
template is greater than genome length, as would occur in conventional HBV 
replication. HBV cccDNA is produced by reverse transcribing the HBV pre-
genomic transcript, which can be recapitulated using this HBV genome 
equivalent. 
 
 pCMV-GFP 
 
 pCMV-GFP is a mammalian expression vector that encodes an enhanced 
green fluorescent fusion protein (EGFP) that expresses green fluorescence 
protein (GFP) (181). It can be used as a reporter plasmid to determine 
transfection efficiency, where higher GFP expression indicates greater 
transfection efficiency. 
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Table 2.1: Descriptions of transfection plasmids 
 
 
 
 
 
 
 
 
Plasmid name Plasmid description Reference
pCH9/3091 HBV equivalent that simulate HBV infection in cell culture [180]
pCMV-GFP 
A reporter plasmid expressing GFP, used to determine transfection 
efficiency 
[181]
pUC118
Standard cloning vector used to ensure consistent DNA quantities for 
transfections 
[182]
C TALEN L Left TALEN subunit targeting the HBV core  ORF [15]
C TALEN R Right TALEN subunit targeting the HBV core  ORF [15]
S TALEN L Left TALEN subunit targeting the HBV surface  ORF [15]
S TALEN R Right TALEN subunit targeting the HBV surface  ORF [15]
Inactive TALEN Left TALEN subunti with an inactive Fok I domain This study
pCI-pri-miR-31/5/8/9 pCI-neo that encode a pri-miR-31/5/8/9 cassette [169]
pri-miR-31/5/8/9 Linear DNA sequence encoding pri-miR-31/5/8/9 [169]
pTZ-C300
pTZ57 plasmid with a three stop codons and restriction enzyme recognition 
sites (Sac I, Cla I and Nhe I), flanked by 300 bp sequences that are 
homologous to the C TALEN recognition site 
K. Bloom
pTZ-S300
pTZ57 plasmid with a three stop codons and restriction enzyme recognition 
sites (Sac I, Cla I and Nhe I), flanked by 300 bp sequences that are 
homologous to the S TALEN recognition sites
K. Bloom
pTZ-C300(pri-miR)
pTZ57 plasmid with a pri-miR cassette, three stop codons and restriction enzyme 
recognition sites (Sac I, Cla I and Nhe I), flanked by 300 bp sequences that are 
homologous to the C TALEN recognition sites
This study
pTZ-S300(pri-miR)
pTZ57 plasmid with a pri-miR cassette, three stop codons and restriction enzyme 
recognition sites (Sac I, Cla I and Nhe I), flanked by 50 bp sequences that are 
homologous to the S TALEN recognition sites
This study
pTZ-C50(pri-miR)
pTZ57 plasmid with a pri-miR cassette, three stop codons and restriction enzyme 
recognition sites (Sac I, Cla I and Nhe I), flanked by 50 bp sequences that are 
homologous to the C TALEN recognition sites
This study
pTZ-S100(pri-miR)
pTZ57 plasmid with a pri-miR cassette, three stop codons and restriction enzyme 
recognition sites (Sac I, Cla I and Nhe I), flanked by 100 bp sequences that are 
homologous to the S TALEN recognition sites
This study
pTZ-pri-miR pTZ57 plasmid with a pri-miR-31/5/8/9 cassette This study
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 pUC118 
 
pUC118 is a standard cloning vector that does not encode a transgene. The 
plasmid was used in these experiments to ensure that all of the DNA quantities 
for the transfections was consistent (182). 
 
 TALENs 
 
TALENs were designed to the core and surface ORF of HBV and are encoded 
on a pVAX TALEN backbone (15). The TALENs were transfected into cells in 
pairs (sense and antisense recognition) to allow for the obligate dimerization of 
the FokI domains to facilitate DNA cleavage. 
 
 
2.1 Donor template construction 
 
2.1.1 Cloning pri-miR-31/5/8/9 into pTZ-C300 and pTZ-S300 vector 
plasmids 
 
The plasmids used to construct the donor templates were obtained from K. 
Bloom. Previously K. Bloom constructed the pTZ-C300 and pTZ-S300 
plasmids which contained 300 bp flanking sequences that are homologous to 
the HBV core and surface ORFs respectively (Figure 2.1 and 2.3 A; Table 2.1). 
These regions contained the TALEN recognition sequence as well as a central 
cassette with three stop codons and several restriction enzyme recognition 
sites (SacI, ClaI and NheI). 
The pTZ-C300 and pTZ-S300 plasmids were modified to act as vector 
backbones by cleaving the plasmids at the NheI site between the flanking 
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homologous regions. Each plasmid was digested with NheI (Thermo Scientific, 
Waltham, MA, USA) in Tango™ 1X buffer (33 mM Tris-acetate (pH 7.9); 10 
mM Mg-acetate; 66 mM K-acetate; 0.1 mg/ml Bovine Serum Albumin (BSA)) 
(Thermo Scientific, Waltham, MA, USA) for 60 minutes at 37°C. The samples 
were incubated for an additional 30 minutes after addition of Fast AP (Thermo 
Scientific, Waltham, MA, USA) to prevent self-annealing of the digested 
plasmids (Figure 2.1). 
Modular trimeric Pol II expression cassettes that encode primary microRNA 
(pri-miR-31/5/8/9) shuttles showed efficient silencing of HBV gene 
expression(169). The pCI-pri-miR-31/5/8/9 plasmid (described by Ely et 
al.(169)) was digested with NheI and XbaI in Tango™ 1X buffer (Thermo 
Scientific, Waltham, MA, USA) for 60 minutes at 37°C to excise the pri-miR-
31/5/8/9 sequence. 
The excised pri-miR-31/5/8/9 (21 ng for pTZ-C300 and 31.6 ng for pTZ-S300) 
with XbaI and NheI overhangs was ligated into the pTZ-C300 (37 ng) and pTZ-
S300 (55 ng) vector backbones by T4 DNA ligase (Thermo Scientific, Waltham, 
MA, USA) (Figure 2.1). The ligation mix consisted of the vector backbones, the 
excised pri-miR sequence, 10x Ligase buffer and T4 DNA ligase, made up to 
20 µl and was incubated for 2 hours at 22°C. 
 
2.1.2 Chemically competent cells and transformation 
 
XL1 Blue Escherichia coli (E. coli) were used to develop competent cells. Cells 
were grown for 16 hours at 37°C in Luria-Bertani (LB) culture medium, diluted 
1:50 in fresh LB and incubated at 37°C until mid-log was reached (OD = 0.4). 
These cells were collected by centrifugation (15 min at 1000 x g and 4°C). The 
pellet was then resuspended in 20 ml transformation buffer (100 mM CaCl; 10 
mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) (pH 7.0); 15% glycerol; 
Chapter 2 
33 
 
pH 7.0; made up to 100 ml with dH2O) and incubated at 4°C for 30 min. After 
incubation cells were collected, resuspended in 1.5 ml transformation buffer, 
aliquoted and stored at -70°C. The ligation mix (5 µl) containing the ligated 
vector backbones and pri-miR-31/5/8/9 cassette was added to 20 µl chemically 
competent cells and mixed gently. The reaction mixture was incubated at 4°C 
for 25 minutes, followed by heat shocking at 42°C for 90 seconds and 
incubation for 2 min at 4°C. The transformed competent cells were plated on 
ampicillin-containing (100 µg/ml) LB agar plates and were incubated at 37°C 
for 16 hours. Picked colonies were cultured in LB medium containing ampicillin 
(100 µg/ml) for 16 hours at 37° in a shaking incubator (Labcon, Gauteng, South 
Africa). 
 
 
2.1.3 Screening for insertion and orientation of pri-miR-31/5/8/9 
 
Plasmid extraction 
 
Successful transformants potentially contain the desired plasmid construct and 
to verify plasmid identity it was necessary to extract and screen the relevant 
plasmids. Plasmids were extracted from the cultured transformants with a 
QIAamp DNA Mini Kit (Qiagen, Venlo, Limburg, Netherlands). Cells were 
collected by centrifugation (30 min at 2800 x g and 4°C). The cell mass was 
then resuspended in PBS (phosphate-buffered saline) and 20 µl Proteinase K 
(24 mg/ml) and 200 µl Buffer AL were added to lyse cells. The cell suspension 
was thoroughly mixed and then incubated at 56°C for 10 min to ensure cell 
lysis. This lysed suspension was inverted and an equivalent volume of 100% 
ethanol was added. The whole mixture was then applied to a QIAmp spin 
column and centrifuged for 1 min at 5900 x g. The plasmid DNA is adsorbed 
onto the QIAamp silica membrane during the centrifugation step. AW1 wash 
buffer was added to the spin column and the centrifugation step was repeated 
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to remove residual contaminants. This was followed by addition of AW2 wash 
buffer to the column and centrifugation for 1 min at 16300 x g to improve the 
purity of the eluted DNA. Distilled H2O was added to the centre of the columns 
and the plasmids were collected by centrifugation (1 min at 5900 x g).  The 
purified plasmids were analysed on a 1% agarose gel (gels were run with a 
PowerPac™ Basic power supply(BioRad, Hercules, CA, USA)), and quantified 
using a Nanodrop ND-1000 Spectrophotometer (Thermo Scientific, Waltham, 
MA, USA). Aliquoted samples were then stored at -20°C. 
 
BamHI/EcoRI and NheI/PciI restriction digest 
 
The purified plasmids (200 ng) were treated with BamHI and EcoRI (Buffer: 10 
mM Tris-HCl (pH 8.0), 5 mM MgCl2, 100 mM KCl, 0.02% Triton X-100, 0.1 
mg/ml BSA) as these restriction sites flank the pri-miR-31/5/8/9 insert and do 
not appear in the vector backbone. Digestion with these enzymes would thus 
indicate successful ligation. Plasmids were screened for inserts that are in the 
same orientation as the cassette in pCI-pri-miR-31/5/8/9 (forward orientation). 
Insert orientation was established using a NheI and PciI double restriction 
digest (Tango™ 1X buffer) and was only performed on those plasmids which 
had been shown to have the necessary insertion. The digested pTZ-C300 and 
pTZ-S300 backbones have two NheI overhangs, whereas the pri-miR shuttle 
has a NheI and XbaI overhang. Therefore, ligation of the backbones and pri-
miR shuttles will result in a single NheI site that will vary in position, depending 
on the orientation of the inserted pri-miR sequence. PciI is a unique restriction 
site in the pTZ-C300 and pTZ-S300 plasmids and does not appear in the pri-
miR insert. Therefore, double enzyme digestion with PciI and NheI will result in 
DNA strands with different lengths as a result of the varying position of the NheI 
restriction site (Figure 2.2). The digested samples were analysed on a 1% 
agarose gel and the samples containing a forward orientated insert were 
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selected for maxiprep. The pTZ-C300 and pTZ-S300 backbones containing the 
forward orientated insert are hereafter referred to as pTZ-C300(pri-miR) and 
pTZ-S300(pri-miR). 
 
pTZ-C300(pri-miR) and pTZ-S300(pri-miR) plasmid extraction 
 
Chemically competent cells were transformed with pTZ-C300(pri-miR) and 
pTZ-S300(pri-miR) and were cultured in LB for 16 hrs at 37°C. To generate 
plasmid stocks for multiple PCR reactions, a QIAGEN Plasmid Maxi Kit 
(Qiagen, Venlo, Limburg, Netherlands) was used to maxiprep the cultured 
transformants. The cultured cells were collected by centrifugation (15 min at 
1000 x g and 4°C) and were resuspended in P1 suspension buffer (50 mM Tris-
HCl (pH 8.0); 10 mM EDTA; 100 μg/ml RNase A). P2 lysis buffer (200 mM 
NaOH; 1% SDS) was added and the cell suspension was inverted and 
incubated at 21°C for 5 min to ensure lysis. After addition of P3 neutralisation 
buffer (3 M potassium acetate (pH 5.5)) to the suspension, the suspension was 
mixed thoroughly, incubated at 4°C for 20 min and centrifuged twice (2x 45 min 
at 2800 x g and 4°C). The supernatant was transferred to a filter column 
(QIAGEN-tip 500) (Qiagen, Venlo, Limburg, Netherlands) that was equilibrated 
with QBT equilibration buffer (750 mM NaCl; 50 mM MOPS (pH 7.0); 15% 
isopropanol; 0.15% triton X-100). Plasmid DNA binds to the column resin 
(under low salt conditions) when the column empties via gravity flow. The 
column was washed twice with medium-salt QC wash buffer (1 M NaCl; 50 mM 
MOPS (pH 7.0); 15% isopropanol) to remove proteins, dyes, RNA and 
impurities, followed by DNA elution with a high-salt QF elution buffer (1.25 M 
NaCl; 50 mM Tris-HCl (pH 8.5); 15% isopropanol). The collected DNA was 
mixed with isopropanol and stored at -20°C for 16 hours to desalt the plasmid 
DNA by isopropanol precipitation. 
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Figure 2.1: Donor template construction. The pTZ-C300 and pTZ-S300 plasmids contain a 
NheI site between the left and right homologous sequences (LHS and RHS) and were 
linearised with a NheI restriction digest. The pri-miR-31/5/8/9 sequence was excised from the 
pCI-pri-miR-31589 plasmid with a NheI/XbaI double restriction digest and then ligated into the 
linear pTZ-C300 and pTZ-S300 vector backbones. 
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The stored DNA was then centrifuged and the DNA pellets were washed with 
70% ethanol. Centrifugation was repeated for 30 min and the DNA pellets were 
left to air dry. The air dried pellets were resuspended in 250 µl distilled H2O, 
quantified by Nanodrop ND-1000 Spectrophotometer, and stored at -20°C. 
 
2.1.4 Linear, double stranded Core and Surface donor template strands 
 
Conventional PCR can be used to produce adequate quantities of double 
stranded, linear donor template strands for transfection experiments. pTZ-
C300(pri-miR) and pTZ-S300(pri-miR) were used as templates to generate 
Core and Surface donor template strands that contain the pri-miR-31/5/8/9 
cassette. The required donor template strands have flanking regions that vary 
in length and are homologous to HBV core and surface target sites (50 bp, 100 
bp, 150 bp and 300 bp respectively), thus, multiple sets of primers were 
required (Figure 2.3). Donor template strands without the pri-miR insert were 
generated with the same primer pairs, using pTZ-C300 and pTZ-S300 (see 
2.2.1) as templates (Figure 2.3). These non-insert donor template strands were 
used as controls to determine if insertion of the pri-miR shuttle into pCH-9/3091 
and the resultant pri-miR expression result in improved HBsAg reduction when 
compared to pCH-9/3091 lacking the pri-miR insert. 
 
Primer design for amplification of the core and surface donor template 
strands 
 
Multiple primer sets were designed to flank the pri-miR insert and its two 
flanking homologous regions. The primers were compared to the pCH9/3091 
plasmid and the pri-miR-31/5/8/9 sequence to ensure lack of similarity to these 
sequences. Primers were analysed and validated with NetPrimer analysis 
software (PREMIER Biosoft International) and were synthesised by Inqaba 
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Biotech (Pretoria, Gauteng, South Africa) using standard phosphoramidite 
technology. A 630 bp region containing 50 bp flanking homologous regions and 
the pri-miR-31/5/8/9 insert (Figure 2.3 B) was amplified from pTZ-C300(pri-
miR) and pTZ-S300(pri-miR) using the following two primer sets: C50-F (928) 
- 5' ATA GAC CAC CAA ATG CCC CTA TC 3' (forward), C50-R (1552) - 5' 
CTG CGA GGC GAG GGA GTT 3' (reverse) and S50-F (928) - 5' GGC GTT 
TTA TCA TCT TCC TC- 3' (forward), S50-R (1550) - 5' GGA ATT AGA GGA 
CAA ACG GG 3' (reverse) (Table 2.2). The following primer sets were used to 
amplify regions of pTZ-C300(pri-miR) and pTZ-S300(pri-miR) that contain the 
prim-miR insert and 100 bp, 150 bp, and 300 bp flanking homologous regions 
respectively: C100-F (878) - 5' TAT AGA GTA TTT GGT GTC TT 3' (forward), 
C100-R (1603) - 5' GAG ATT CCC GAG ATT GA 3' (reverse), C150-F (828) - 
5' CAA CTC TTG TGG TTT CAC AT 3' (forward), C150-R (1650) - 5' TAA AGC 
CCA GTA AAG TTC CC 3' (reverse), C300-F (678) - 5' TCA CCT CAC CAT 
ACT GC 3' (forward), C300-R (1802) - 5' GCA GGC ATA ATC AAT TGC 3' 
(reverse), S100-F (878) - 5' ACC AAC CTC TTG TCC TCC AA 3' (forward), 
S100-R (1601) - 5' CAG TAG TCA TGC AGG TCC G 3' (reverse), S150-F (828) 
- 5' ACT ACC GTG TGT CTT GGC C 3' (forward), S150-R (1650) - 5' GTC 
CGA AGG TTT GGT ACA GC 3' (reverse), S300-F (678) - 5' GGG GAC CCT 
GCG CTG AAC 3' (forward) and S300-R (1798) - 5' AAC TGA AAG CCA AAC 
AGT GGG G 3'(reverse) (Table 2.2). The primer sets generated Core and 
Surface donor template strands (amplicons) that were 630 bp (C50(pri-miR); 
S50(pri-miR)), 730 bp (C100(pri-miR); S100(pri-miR)), 830 bp (C150(pri-miR); 
S150(pri-miR)) and 1130 bp (C300(pri-miR); S300(pri-miR)) in length (Table 
2.3). The same primer sets were used to amplify 121 bp (C50; S50), 221 bp 
(C100; S100), 321 bp (C150; S150) and 621 bp (C300; S300) regions within 
the pTZ-C300 and pTZ-S300 plasmids (see 2.2.1) (Table 2.2). These regions 
contain the donor template strands with homologous regions but lack the pri-
miR insert (Figure 2.3 A). 
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Figure 2.2: Orientation of the integrated pri-miR-31/5/8/9 sequence. The pTZ-C300 and 
pTZ-S300 plasmids containing the pri-miR-31/5/8/9 insert were digested with PciI and NheI. 
The PciI restriction site is a unique site. The location of the NheI site after ligation depends on 
the orientation of the inserted pri-miR-31/5/8/9 sequence. The NheI site is closer to the plasmid 
origin (the 0 position on the plasmid) if the inserted sequence is in a forward orientation and a 
NheI/PciI double digest should result in a 1207 bp and 2796 bp band. The NheI site is further 
from the plasmid origin if the insert is reverse orientated and should result in a 698 bp and 3306 
bp band when double digested with NheI and PciI. 
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PCR amplification of the donor template strands 
 
pTZ-C300(pri-miR), pTZ-S300(pri-miR), pTZ-C300 and pTZ-S300 (see 2.2.1) 
were used as amplification templates. The PCR system for all Core donor 
template strand amplifications included 2x KAPA Taq RM (Kapa Biosystems, 
Wilmington, Massachusetts, USA), 10 µM Cxx-F forward primer, 10 µM Cxx-R 
reverse primer, and 100-150 ng pTZ-C300(pri-miR) and pTZ-C300, made up 
to a final volume of 50 µl with distilled H2O (dH2O) in a 0.2 ml PCR grade 
microcentrifuge tube (Axygen Scientific, Union City, CA, USA). The PCR 
components used for Surface donor template strand amplifications were: 2x 
KAPA Taq RM, 10 µM Sxx-F forward primer, 10 µM Sxx-R reverse primer, and 
100-150 ng  pTZ-300(pri-miR) and pTZ-S300, made up to 50 µl with dH2O. The 
PCRs were performed in a Bio Rad T100™ Thermal cycler (BioRad, Hercules, 
CA, USA) under the following conditions: initial denaturation at 95°C for 2 min; 
30 cycles of: denaturation at 95°C for 30s, annealing at x°C for 30s (depending 
on which primer set is used) and extension at 72°C for 1 min; final elongation 
at 72°C for 2 min, followed by cooling at 4°C (Table 2.3). The annealing 
temperature for each primer set was calculated by subtracting 5°C from the 
primer melting temperatures (Tm) listed in Table 2.2. The PCR products were 
analysed on 1% agarose gels and quantified with a Nanodrop ND-1000 
Spectrophotometer. 
A Gene JET PCR Purification Kit (Thermo Scientific, Waltham, MA, USA) was 
used to remove primers, dNTPs, unincorporated labelled nucleotides, enzymes 
and salts from PCR mixtures to use the donor template strands for transfection 
experiments (Table 2.4). An equal volume of Binding buffer was added to the 
completed PCR mixtures and transferred to a GeneJET purification column. 
The proteins in the solution are denatured by a chaotropic agent in the binding 
buffer, which also promotes DNA binding to the proprietary silica-based 
membrane. The suspension was centrifuged (60 seconds at 16300 x g), 
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followed by addition of Wash buffer to remove impurities. Residual wash buffer 
was removed by repeating the previous centrifugation step twice, followed by 
addition of Elution buffer (10 mM Tris-HCl (pH 8.5)) to collect the donor 
template strands. The purified donor template strands were analysed with a 1% 
agarose gel, quantified with a Nanodrop ND-1000 Spectrophotometer and 
stored at -20°C.
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Figure 2.3: Core and Surface donor template strands. Donor template strands with flanking sequences that are homologous to the C and 
S TALEN target sites were generated by PCR. The length of the flanking homology arms were varied (50, 100, 150 and 300 bp respectively) 
to analyse their effect on HDR efficiency. A: Donor template strands without the pri-miR-31/5/8/9 insert were constructed as controls. B: Donor 
template strands containing the pri-miR-31/5/8/9 sequence that will be incorporated at the pCH-9/3091 target site. The primers are listed in 
Table 2.2.
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Table 2.2: Forward and reverse primers used to generate the donor 
template strands 
Name Sequence Tm (°C) 
50 bp Core (forward) 5' ATAGACCACCAAATGCCCCTATC 3' 62.77 
50 bp Core (reverse) 5' CTGCGAGGCGAGGGAGTT 3' 64.46 
      
100 bp Core (forward) 5' TATAGAGTATTTGGTGTCTT 3' 52.2 
100 bp Core (reverse) 5' GAGATTCCCGAGATTGA 3' 54.78 
      
150 bp Core (forward) 5' CAACTCTTGTGGTTTCACAT 3' 56.3 
150 bp Core (reverse) 5' TAAAGCCCAGTAAAGTTCCC 3' 58.35 
      
300 bp Core (forward) 5' TCACCTCACCATACTGC 3' 57.19 
300 bp Core (reverse) 5' GCAGGCATAATCAATTGC 3' 55.34 
      
50 bp Surface (forward) 5' GGCGTTTTATCATCTTCCTC 3' 58.35 
50 bp Surface (reverse) 5' GGAATTAGAGGACAAACGGG 3' 60.4 
      
100 bp Surface (forward) 5' ACCAACCTCTTGTCCTCCAA 3' 60.4 
100 bp Surface (reverse) 5' CAGTAGTCATGCAGGTCCG 3' 62.32 
      
150 bp Surface (forward) 5' ACTACCGTGTGTCTTGGCC 3' 62.32 
150 bp Surface (reverse) 5' GTCCGAAGGTTTGGTACAGC 3' 62.45 
      
300 bp Surface (forward) 5' GGGGACCCTGCGCTGAAC 3' 66.73 
300 bp Surface (reverse) 5' AACTGAAAGCCAAACAGTGGGG 3' 62.67 
 
 
Table 2.3: Temperature and time for each PCR cycle 
 
Temperature 
(°C) 
Time 
(min) 
Initial denaturation 95°C 2 
Denaturation 95°C 0.5 
Annealing Tm 0.5 
Extension 72°C 1 
Final extension 72°C 2 
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Table 2.4: Descriptions of donor template strands 
 
 
 
 
 
 
Donor template 
strand name
Donor template strand description Reference
C50
Core donor template strand with three stop codons and restriction enzyme 
recognition sites flanked by 50 bp homologous sequences
This study
C100
Core donor template strand with three stop codons and restriction enzyme 
recognition sites flanked by 100 bp homologous sequences
This study
C150
Core donor template strand with three stop codons and restriction enzyme 
recognition sites flanked by 150 bp homologous sequences
This study
C300
Core donor template strand with three stop codons and restriction enzyme 
recognition sites flanked by 300 bp homologous sequences
This study
C50(pri-miR)
Core donor template strand with pri-miR-31/5/8/9 flanked by 50 bp homologous 
sequences
This study
C100(pri-miR)
Core donor template strand with pri-miR-31/5/8/9 flanked by 100 bp homologous 
sequences
This study
C150(pri-miR)
Core donor template strand with pri-miR-31/5/8/9 flanked by 150 bp homologous 
sequences
This study
C300(pri-miR)
Core donor template strand with pri-miR-31/5/8/9 flanked by 300 bp homologous 
sequences
This study
S50
Surface donor template strand with three stop codons and restriction enzyme 
recognition sites flanked by 50 bp homologous sequences
This study
S100
Surface donor template strand with three stop codons and restriction enzyme 
recognition sites flanked by 100 bp homologous sequences
This study
S150
Surface donor template strand with three stop codons and restriction enzyme 
recognition sites flanked by 150 bp homologous sequences
This study
S300
Surface donor template strand with three stop codons and restriction enzyme 
recognition sites flanked by 300 bp homologous sequences
This study
S50(pri-miR)
Surface donor template strand with pri-miR-31/5/8/9 flanked by 50 bp homologous 
sequences
This study
S100(pri-miR)
Surface donor template strand with pri-miR-31/5/8/9 flanked by 100 bp 
homologous sequences
This study
S150(pri-miR)
Surface donor template strand with pri-miR-31/5/8/9 flanked by 150 bp 
homologous sequences
This study
S300(pri-miR)
Surface donor template strand with pri-miR-31/5/8/9 flanked by 300 bp 
homologous sequences
This study
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2.2 Transfection of cultured Huh7 cells with TALENs and donor 
template strands 
 
2.2.1 Huh7 cell culture 
 
Huh7 cells, a liver derived human hepatoma cell line that supports viral 
replication when transfected with HBV DNA, were used to quantify the total 
HBsAg generated in a cell culture model system (183, 184). The cells were 
cultured in Cellstar® 75 cm3 cell culture flasks (Greiner Bio-One GmbH, 
Frickenhausen, Germany) using Dulbeco’s Modified Eagles Medium (DMEM) 
(Gibco, Invitrogen, USA) supplemented with 10% foetal bovine serum (FBS) 
(Biochrom GmbH, Berlin, Germany). The cultured cells were maintained at 
37°C and 5% CO2 in a humidified incubator until the cells covered 90-100% of 
the flask base (90-100% confluent). Cell confluency was analysed with a 
Olympus CKX31 light microscope (Olympus, Shinjuku, Tokyo, Japan) at 10x 
magnification.  
The cell culture supernatant was removed and the adherent cells were washed 
with PBS. Washed cells were removed by trypsinisation (TrypLE™, Carlsbad, 
CA, United States of America) followed by resuspension in fresh DMEM growth 
medium. The cell suspension (4.8-5.3 x 105 cells/ml) was distributed in a 24 
well Cellstar® Cell Culture Plate (Greiner Bio-One GmbH, Frickenhausen, 
Germany) (500 µl per well) and maintained in a humidified incubator at 37°C 
and 5% CO2 until the cells were 80-90% confluent. Fresh DMEM growth 
medium was added to the confluent cultured cells just prior to transfection. 
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2.2.2 Transfecting cultured Huh7 cells 
 
Each transfection sample consisted of a total 2 µg DNA (Table 2.5). The Core 
transfection samples consisted of the following (plasmids and donor template 
strands listed in Table 2.1 and 2.4): 200 ng pCH-9/3091; 100 ng pCMV-GFP; 
pUC118; 350 ng left C TALEN subunit (CPL); 350 ng right C TALEN subunit 
(CPR); 1 µg donor template strands (C50(pri-miR), C100(pri-miR), C150(pri-
miR) and C300(pri-miR)) (Table 2.5), made to a final volume of 25 µl. The 
components in the Surface transfection samples were the same as those of the 
Core transfection samples, except CPL and CPR were substituted with SPL 
and SPR and the Core donor template strands were substituted with the 
Surface donor template strands (S50(pri-miR), S100(pri-miR), S150(pri-miR) 
and S300(pri-miR)) (Table 2.5). A third and fourth set of Core and Surface 
transfection samples substituted the insert-containing donor template strands 
with donor template strands that have three stop codons and no pri-miR-
31/5/8/9 insert (C50, C100, C150, C300, S50, S100, S150 and S300) (Table 
2.5). A mock (containing 200 ng pCH-9/3091, 100 ng pCMV-GFP, and 1.7 µg 
pUC118) as well as negative controls (containing an inactive left surface 
TALEN constructed by S. Nicholson (Table 2.1)) were also included (Table 
2.5). Each transfection was done in triplicate. 
Cells were transfected with polyethylenimine (PEI) (185, 186). Equal volumes 
of PEI (mg/ml) were added to each sample. The samples were thoroughly 
mixed and incubated at 21°C for 10 min. The incubated samples were then 
added drop wise to the cultured cells. The transfected cells were maintained in 
a humidified incubator at 37°C and 5% CO2 for 24 hours, followed by addition 
of fresh DMEM growth medium and incubation for 48 hours. 
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Table 2.5: DNA amounts for Huh7 transfection in 24 well plates 
Mock ng C TALENs ng 
Core donor template strands 
with pri-miR 
ng 
Donor template strands 
without pri-miR 
ng 
pCMV-GFP 100 pCMV-GFP 100 pCMV-GFP 100 pCMV-GFP 100 
pCH-9/3091 200 pCH-9/3091 200 pCH-9/3091 200 pCH-9/3091 200 
pUC-118 1700 pUC-118 1000 pUC-118 0 pUC-118 0 
    CPR 350 CPR 350 CPR 350 
    CPL 350 CPL 350 CPL 350 
        
Core donor template strands with 
pri-miR 
1000 
Donor template strands without 
pri-miR 
1000 
Total 2000 Total 2000 Total 2000 Total 2000 
 
S TALENs ng 
S donor template 
strands with pri-miR 
ng 
S donor template 
strands without 
pri-miR 
ng 
Inactive 
TALEN 
ng 
Inactive TALEN + C 
donor template strands 
with pri-miR 
ng 
pCMV-GFP 100 pCMV-GFP 100 pCMV-GFP 100 pCMV-GFP 100 pCMV-GFP 100 
pCH-9/3091 200 pCH-9/3091 200 pCH-9/3091 200 pCH-9/3091 200 pCH-9/3091 200 
pUC-118 1000 pUC-118 0 pUC-118 0 pUC-118 1000 pUC-118 0 
SPR 350 SPR 350 SPR 350 
inactive 
TALEN 
700 inactive TALEN 700 
SPL 350 SPL 350 SPL 350     
Inactive TALEN + C donor 
template strands with pri-
miR 
1000 
    
S donor template 
strands with pri-miR 
1000 
S donor template 
strands without pri-
miR 
1000         
Total 2000 Total 2000 Total 2000 Total 2000 Total 2000 
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2.3 Analysis 
 
2.4.1 GFP 
 
GFP expression by the transfected Huh7 cells was analysed with 488 nm and 
509 nm excitation and emission wavelengths respectively using a Zeiss 
Axiovert 100 M fluorescence microscope (Carl-Zeiss, Oberkochen, Germany). 
 
2.4.2 HBsAg ELISA 
 
Huh7 cells transfected with pCH-9/3091, an HBV equivalent, produces HBsAg, 
thus simulating natural HBV replication. The effect of TALENs and donor 
template strands on HBV activity can be analysed by measuring the HBsAg 
concentration of the transfected cells, where a decrease in HBsAg 
concentration indicates reduced viral activity. The HBsAg levels were 
measured using an HBsAg enzyme-linked immunosorbent assay (ELISA), 
which is a one-step enzyme immune assay technique for the detection of HBV 
surface antigen.  
HBsAg concentrations were measured with a Monolisa HBsAg Ultra kit 
(BioRad, Hercules, CA, USA). The supernatants (100 μl) of transfected cells 
were collected and distributed in a microplate with mouse monoclonal anti-
HBsAg antibody coated wells. Conjugate working solution (mouse monoclonal 
anti-HBsAg antibodies and goat polyclonal anti-HBsAg antibodies which binds 
to the peroxidase) was added and aspirated with a pipette. The microplate was 
then covered with adhesive film and incubated at 37°C for 1 hour and 30 
minutes. The unbound conjugate was removed by washing the microplate wells 
5 times with washing buffer (Tris-NaCl (pH 7.4); 0.04% ProClin™ 300 
(preservative)), using an Immuno Wash™ 1575 Microplate Washer (BioRad, 
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Hercules, CA, USA). Development solution (Citric acid and Sodium acetate 
solution (pH 4); 0.015% H2O2; 4% Dimethyl sulfoxide (DMSO)) was added to 
the wells, followed by incubation in the dark at 21°C for 30 minutes, after which 
the reaction was terminated by addition of stopping solution (1N sulphuric acid 
solution). After 5 minutes the optical densities of the samples were read at 450-
620/700 nm using a Model 680 Microplate Reader (BioRad, Hercules, CA, 
USA). The results were printed for analysis. 
 
2.4.3 PCR analysis of pri-miR-31/5/8/9 integration sites 
 
DNA extraction from transfected Huh7 cells 
 
The transfected Huh7 cells were loosened with a rubber cell scraper and the 
pCH-9/3091 plasmids from the collected cells were extracted with a QIAamp 
DNA Mini Kit (Qiagen, Venlo, Limburg, Netherlands) for PCR analysis. 
 
PCR amplification of the pCH-9/3091 core and surface insertion sites 
 
Primers were designed to amplify the core and surface target sites to confirm 
successful insertion of the pri-miR-31/5/8/9 cassette. A forward primer was 
designed to bind to the inserted pri-miR sequence and two reverse primers 
were designed to bind regions downstream of the insert and the right flanking 
homologous sequence of the core and surface target sites respectively (Figure 
2.4). This design ensures that the insert site is amplified if the pri-miR-31/5/8/9 
sequence was successfully integrated at the core or surface target sites. The 
primers were compared with the pCH9/3091 plasmid and the pri-miR-31/5/8/9 
sequence to ensure lack of similarity to these sequences. Oligonucleotide 
primers were analysed and validated with NetPrimer analysis software 
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(PREMIER Biosoft International) and were synthesised by Inqaba Biotech 
(Pretoria, Gauteng, South Africa). The core insert site was amplified from pCH-
9/3091 using the following primer set: Insert-F (459) - 5' CTG ATC ATC GAT 
AGC TAG CC 3' (forward) and InsertC-R (1067) - 5' GAG ATT CCC GAG ATT 
GAG AT 3' (reverse) (Table 2.6).  The same forward primer (1733) and InsertS-
R (2914) - 5' AAG TTG GCG AGA AAG TGA A 3' (reverse) were used to amplify 
the surface insert site from pCH-9/3091. The PCR system for core site 
amplification included 2x KAPA Taq RM (Kapa Biosystems, Wilmington, 
Massachusetts, USA), 10 µM Insert-F forward primer, 10 µM InsertC-R reverse 
primer, and 100-150 ng  purified plasmid, made up to a final volume of 25 µl 
with dH2O in a 0.2 ml PCR grade microcentrifuge tube (Axygen Scientific, 
Union City, CA, USA). The components for surface site amplification are the 
same as for the core site amplification except for the substitution of InsertC-R 
reverse primer with InsertS-R reverse primer. The PCRs were performed in a 
BioRad T100™ Thermal cycler (BioRad, Hercules, CA, USA) under the 
following conditions: initial denaturation at 95°C for 2 min; 30 cycles of: 
denaturation at 95°C for 30s, annealing at xx°C for 30s (depending on which 
primer set is used) and extension at 72°C for 1 min; final elongation at 72°C for 
2 min, followed by cooling at 4°C (Table 2.3). The annealing temperature for 
each primer set was calculated by subtracting 5°C from the primer melting 
temperatures (Tm) listed in Table 2.6. The PCR products were analysed on a 
1% agarose gel and stored at -20°C. 
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Table 2.6: PCR primers for analysis of pri-miR-31/5/8/9 integration into 
pCH-9/3091 
Name Sequence Tm (°C) 
Insert-F (forward) 5' -CTGATCATCGATAGCTAGCC- 3' 60.4 
      
InsertC-R (reverse) 5' -GAGATTCCCGAGATTGAGAT- 3' 58.35 
      
InsertS-R (reverse) 5' -AAGTTGGCGAGAAAGTGAA- 3' 55.85  
      
 
 
 
 
 
 
 
 
Figure 2.4: PCR analysis confirming integration of the pri-miR-31/5/8/9 cassette and 
three stop codons into pCH-9/3091. A forward primer binds a target sequence within the 
region containing the 3 stop codons and a reverse primer binds a target sequence within the 
pCH-9/3091 plasmid. The primer pair should not amplify the donor template and should only 
yield products if the insert (3 stop codons and the pri-miR-31/5/8/9 cassette) is present within 
the pCH-9/3091 plasmid. 
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2.4.4 Sequencing of the PCR products 
 
The PCR products from the PCR integration analysis have to be sequenced to 
confirm successful insertion of the pri-miR-31/5/8/9 cassette at the core and 
surface target sites. Extraction of the PCR products from the 1% agarose gels 
was carried out using a QIAquick Gel Extraction Kit (Qiagen, Venlo, Limburg, 
Netherlands). DNA bands were excised using a clean, sharp scalpel and were 
suspended in 3 volumes of QG buffer (5.5 M guanidine thiocyanate; 20 mM 
Tris-HCl (pH 6.6)).  The suspended gel fragments were incubated at 50°C for 
10 min to dissolve the gel, followed by addition of one gel volume of 
isopropanol. The mixture was applied to a QIAquick spin column and 
centrifuged for 1 minute at 16300 x g. This was followed by addition of QG 
buffer and centrifugation (1 minute at 16300 x g). The column was then washed 
with Buffer PE (10 mM Tris-HCl (pH 7.5); 80% ethanol) and incubated for 3 min 
at 21°C, followed by centrifugation at 16300 x g for 1 minute. Centrifugation 
was repeated to remove residual wash buffer. Distilled H2O was added to the 
centre of the column and the plasmids were collected by centrifugation (1 min 
at 5900 x g). 
The collected DNA was purified using the Gene JET PCR Purification Kit (see 
2.2.4), quantified using a Nanodrop ND-1000 Spectrophotometer, and 
sequenced by Inqaba Biotech (Gauteng, Pretoria, RSA).  
To determine whether the pri-miR insert was successfully incorporated into 
pCH-9/3091, multiple sequence alignments were performed between the target 
core and surface sites, and the Inqaba Biotech sequencing results. These 
sequences were aligned and evaluated with BLASTN (187, 188). 
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2.4.5 pri-miRNA expression analysis 
 
Cloning donor template strands into pTZ57 plasmids 
 
The donor template strands were cloned into pTZ57 R/T plasmids for 
production of large plasmid quantities required for transfection of cells in 10 cm 
plates. 
The plasmids containing the required C300(pri-miR) and S300(pri-miR) donor 
template strands were previously constructed in 2.1.1 (see Table 2.1: pTZ-
C300(pri-miR) and pTZ-S300(pri-miR)). C50(pri-miR) and S100(pri-miR) donor 
template strands were respectively cloned into pTZ57 R/T plasmids with an 
InsTAclone™ PCR Cloning Kit (Thermo Scientific, Waltham, MA, USA). The 
ligation reaction was set up as follows: 4 µl of 5x ligation buffer, 0.165 µg of 
pTZ57 R/T, 7.5 U of T4 DNA ligase and 0.1 µg of either C50(pri-miR) or 
S100(pri-miR), made up to a final volume of 20 µl in a 1.5 ml microcentrifuge 
tube. The reaction mixture was then incubated at 21°C for 2 hours and added 
to chemically competent cells. These chemically competent cells were 
transformed and cultured as in 2.1.2.  
The plasmids (pTZ-C50(pri-miR) and pTZ-S100(pri-miR)) (Table 2.1) were 
purified using a QIAamp DNA Mini Kit (Qiagen, Venlo, Limburg, Netherlands), 
as described in 2.1.3. Once successfully extracted, transformants were 
screened for insertion of C50(pri-miR) and S100(pri-miR). This was established 
using PvuII restriction digest. The purified plasmids (200 ng) were treated with 
PvuII as this restriction site flanks the insert and does not appear in the vector 
backbone, indicating successful ligation. 
The artificial pri-miR-31/5/8/9 cassette was also cloned and purified, following 
the same cloning, purification and enzyme digestion protocols as with C50(pri-
miR) and S100(pri-miR), except for the substitution of C50(pri-miR) and 
S100(pri-miR) with the pri-miR-31/5/8/9 sequence. The pTZ57 R/T plasmids 
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containing the C50(pri-miR), S100(pri-miR) and pri-miR-31/5/8/9 insert will 
hereafter be referred to as C50(pri-miR), S100(pri-miR) and pTZ-pri-miR 
respectively (Table 2.1). 
Large quantities of C50(pri-miR), S100(pri-miR and pTZ-pri-miR are required 
for transfecting large cell volumes. Therefore, chemically competent cells were 
transformed with C50(pri-miR), S100(pri-miR and pTZ-pri-miR respectively and 
were cultured in LB medium for 16 hrs at 37°C. A QIAGEN Plasmid Maxi Kit 
(Qiagen, Venlo, Limburg, Netherlands) was used to maxiprep the cultured 
transformants, as described in 2.1.3. 
 
Cell culturing and transfection 
 
Huh7 cells were cultured in Cellstar® 175 cm2 cell culture flasks (Greiner Bio-
One GmbH, Frickenhausen, Germany) using DMEM growth medium 
supplemented with 10% FBS. The cultured cells were maintained at 37°C and 
5% CO2 in a humidified incubator until confluent.  
The cell culture supernatant was removed and the adherent cells were washed 
with PBS. Washed cells were removed by trypsinisation, followed by 
resuspension in fresh DMEM growth medium. No wash step was required as 
TrypLE™ is used to dissociate cells, not porcine trypsin. The cell suspension 
was then distributed in 10 cm plates (Greiner Bio-One GmbH, Frickenhausen, 
Germany) and maintained in a humidified incubator at 37°C and 5% CO2 until 
the cells reached 80-90% confluency. Fresh DMEM growth medium was added 
to the confluent cultured cells just prior to transfection. 
Each transfection sample consisted of a total 25 µg DNA. The core transfection 
samples consisted of the following (Table 2.7): 3 µg pCH-9/3091; 2 µg pCMV-
GFP; pUC118; 4 µg left C TALEN subunit (CPL); 4 µg right C TALEN subunit 
(CPR); 12 µg donor template (pTZ-C50(pri-miR) and pTZ-C300(pri-miR)); 250 
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mM NaCl, made up to a final volume of 500 µl with dH2O (see Table 2.1 for 
plasmid descriptions). The components in the surface transfection samples 
were the same as those of the core transfection samples, except for the 
substitution of the left and right C TALENs with the left and right S TALENs 
(SPL and SPR) as well as substitution of the Core donor template strands with 
the Surface donor template strands (pTZ-S100(pri-miR) and pTZ-S300(pri-
miR)). In two of the surface samples the Surface donor template strands were 
exchanged with pTZ-pri-miR to analyse the effect of the pri-miR-31/5/8/9 
cassette without the flanking homologous regions. A positive control 
(containing 3 µg pCH-9/3091, 2 µg pCMV-GFP, and 20 µg pCI-pri-miR-31589, 
a plasmid that expresses pri-miRNA when transfected(169)) was also included. 
Equal volumes of PEI were added to each transfection sample, bringing each 
sample to a final volume of 1 ml. The samples were thoroughly mixed and 
incubated at 21°C for 10 min. The incubated samples were then added drop 
wise to the cultured cells. The transfected cells were maintained in a humidified 
incubator at 37°C and 5% CO2 for 24 hours, followed by addition of fresh DMEM 
growth medium and incubation for an additional 48 hours. 
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Table 2.7: Huh7 transfection DNA amounts for 10 cm plates 
Pri-miR control μg 
Donor template 
strands 
μg Linear pri-miR μg 
Linear pri-miR 
with S TALENs 
μg 
pCMV-GFP 2 pCMV-GFP 2 pCMV-GFP 2 pCMV-GFP 2 
pUC-118 0 pUC-118 0 pUC-118 8 pUC-118 0 
pCH-9/3091 3 pCH-9/3091 3 pCH-9/3091 3 pCH-9/3091 3 
pCI-pri-miR-31589 20 CPL 4 pTZ-pri-miR 12 SPL 4 
  
 
CPR 4   
 
SPR 4 
  
 
Donor template 
strands with pri-miR 
12   
 
pTZ-pri-miR 12 
  
 
  
 
  
 
  
 
Total 25 Total 25 Total 25 Total 25 
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RNA isolation 
 
Transfected cells were collected with a cell scraper, centrifuged (5 min at 50 x 
g), and resuspended in Tri-reagent (contains guanidine thiocyanate and phenol 
in a monophase solution) (Sigma-Aldrich, St. Louis, MO, USA). The 
resuspended cells were thoroughly mixed and incubated at room temperature 
for 5 minutes to ensure lysis. This was followed by addition of chloroform and 
incubation for 10 min at 21°C. Samples were then centrifuged for 10 minutes 
at 13300 x g and 4°C. The top aqueous phase was transferred to a 2 ml 
microcentrifuge tube and isopropanol was added. The samples were inverted 
and incubated at 21°C for 10 min, followed by centrifugation at 13300 x g and 
4°C for 10 min. The pellets were washed with 75% ethanol in 
diethylpyrocarbonate (DEPC) water (Ambion®, Austin, Texas, USA). The 
washed pellets were vortexed briefly and centrifuged at 13300 x g and 4°C for 
5 min. Finally, the pellets were air dried for 10 minutes and resuspended in 100 
µl RNase free water. The isolated RNA was viewed on a 1% agarose gel and 
quantified using a Nanodrop ND-1000 Spectrophotometer. Samples were 
aliquoted (30 µg/15 µl) and stored at -70°C. 
 
Radiolabeled RNA molecular weight markers 
 
All work involving radioactive material was done behind a shield to protect the 
body from damaging radiation and all solid and liquid radioactive waste was 
discarded in allocated radioactive waste drums. A series 900 mini-monitor 
(Saint-Gobain, Courbevoie, France) was used to monitor radiation levels at all 
times. 
Radiolabeled RNA molecular weight markers were generated with an 
Ambion®Decade™ Markers System (Ambion®, Austin, Texas, USA). The 
radiolabelled molecular markers included 100 ng RNA, nuclease free H2O, 10x 
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kinase reaction buffer A, [γ-32P]ATP (≥ 3000 Ci/mmol) and T4 polynucleotide 
kinase that were mixed and incubated at 37°C for 1 hour. Both nuclease free 
H2O and 10x cleavage reagent were added after the 1 hour incubation, followed 
by incubation at 21°C for 5 min. The molecular weight marker solution was then 
mixed with gel loading buffer II and stored at 4°C. 
 
Acrylamide gel 
 
A 15% acrylamide gel was set on the day before loading the RNA samples and 
molecular weight markers. The gel solution consisted of the following: bis-
acrylamide and acrylamide at a 1:19 ratio, 8 M urea, and 10x Tris-borate-EDTA 
(TBE) (1 M boric acid, 0.2 M Ethylenediaminetetraacetic acid (EDTA) and 1 M 
Tris-Cl, pH 8), made up to 60 ml with dH2O and heated to dissolve the contents. 
Newly made 1% ammonium persulphate (APS) (250 μl) and 
tetramethylethylenediamine (TEMED) (25 μl) (Sigma-Aldrich, St. Louis, MO, 
USA) were added to the gel mixture to catalyse the polymerization of 
acrylamide and bis-acrylamide. The gel was poured in a SE400 Vertical Slab 
Gel Electrophoresis Unit (GE Healthcare Life Sciences, Piscataway, NJ, USA). 
Once the gel was set, the comb was removed and the gel apparatus buffer 
tanks were filled with 0.5x TBE buffer. The gel ran at 150 V for 30 minutes and 
then the wells were flushed with a Hamilton syringe to remove residual buffer 
at the bottom of the wells. The 15 µl aliquoted RNA samples were mixed with 
15 µl gel loading buffer II, followed by 5 min denaturation of the RNA samples 
and the RNA molecular weight markers at 80°C and 95°C respectively. The 
denatured samples were incubated at 4°C for 5 min and then loaded onto the 
gel. The samples ran on the gel for 5 hours (150V and 4°C), after which the gel 
was removed and stained with 0.01% ethidium bromide (EtBr) in 0.5x TBE 
buffer for 5 min. 
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The samples were transferred to a hybond positively charged nylon membrane 
(GE Healthcare Life Sciences, Piscataway, NJ, USA) for treatment with the 
radioactive probe. The gel was placed on the nylon membrane and sandwiched 
between six 3 mm filter paper sheets (3 underneath and 3 on top) that were 
soaked in 0.5x TBE buffer. Excess buffer was removed and the samples were 
transferred for 45 min using a Sigma Aldrich SV20-SDB gel transfer system 
(Sigma-Aldrich, St. Louis, MO, USA) at 0.76 A and 4°C. The membrane was 
then transferred to new dry blotting paper and placed in a UV cross linker (120 
milliJoules/cm2 for 20 seconds) to immobilise the RNA on the membrane. After 
UV cross linking RNA solubilising H2O was removed from the membrane by 
incubating the membrane for 1 hour at 80°C.  
The Decade™ Marker ladder was cut from the membrane and stored in a Bass 
cassette II case for 24 hours, with an imaging plate placed over the ladder. The 
imaging plate was then placed in a Fujifilm FLA7000 image reader to view the 
Decade™ ladder. On completion, the imaging plate was erased in an IPEraser 
3 and the membrane was discarded in a radioactive waste bin. 
 
Radioactive labelling of the probe 
 
The radiolabelled probe included the following: Polynucleotide kinase (PNK) 
buffer A, 10 μM miR-31/5 guide probe oligonucleotide(169), and [γ-32P]ATP (≥ 
3000 Ci/mmol) radioactive labels, made up to a final volume of 20 µl with dH2O. 
The probe-radiolabel mixture was then incubated at 37°C for 30 minutes and 
stored at 4°C. 
Half a millilitre compacted filter floss was placed at the bottom of a 1 ml 
disposable syringe (Neomedic Ltd, Rickmansworth, Hertfordshire, United 
Kingdom) to prepare the Sephadex column required to purify the radiolabelled 
probe. Sephadex G-25 was added to the syringe, which was centrifuged inside 
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a 15 ml falcon tube at 700 x g for 2 minutes. This process was repeated until 
the Sephadex column volume was approximately 0.8 ml (approximately 0.4 g 
Sephadex). The final volume of the radiolabelled probe was made up to 50 µl 
with dH2O, after which the probe was applied to the Sephadex column. The 
purified probe was then collected in the 15 ml falcon tube by centrifugation (700 
x g for 2 min) and stored at 4°C. 
 
Hybridisation 
 
The membrane was placed in a hybridisation bottle with hybridisation buffer 
(Sigma-Aldrich, St. Louis, MO, USA) that was heated to 42°C. This was 
followed by incubation of the membrane and buffer at 42°C for 20 minutes. The 
labelled probe was denatured at 95°C for 5 min and added to the membrane. 
The membrane was then hybridised in a hybridisation oven at 42°C for 16 
hours. 
 
Stringency washes and exposure 
 
The hybridisation buffer was discarded and the membrane was washed with 
5x SSC (20x SSC: 3M NaCl, 0.3M Na3C6H5O7.2H2O, distilled H2O, pH 7) and 
0.1% sodium dodecyl sulphate (SDS) for 20 min at 21°C. This was followed 
by two 1x SSC and 0.1 % SDS washes at 42°C for 15 minutes per wash. The 
membrane was then placed in a plastic sleeve and stored with an imaging 
plate in a Bass cassette II for 7 days at 21°C. After 7 days the membrane was 
analysed in a Fujifilm FLA7000. The imaging plate was erased and the 
membrane was discarded in the solid radioactive waste bin. 
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2.5 Statistical analysis 
 
All HBsAg quantifications were carried out in triplicate for each sample type 
and condition, unless otherwise stated. GraphPad Prism version 5.00 
(GraphPad software, San Diego, CA, USA) was used to perform two-tailed 
paired and unpaired Student’s t tests. P values of < 0.05 were regarded as 
statistically significant and data is represented as the mean ± the standard error 
of the mean (SEM).
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3. Results 
 
3.1 Donor template strand construction 
 
HDR uses a homologous template to repair DSBs and can be exploited to insert 
an artificial DNA sequence at the DNA break (163, 165-167). To that end we 
designed a donor template strand that contains an anti-HBV pri-miR-31/5/8/9 
cassette without a promoter (Figure 3.1). The rational was that HDR, stimulated 
by TALEN-mediated DSBs, would recognise the flanking homologous 
sequences of the donor DNA strands and utilise it as donor templates to repair 
the DSB. HDR would then incorporate the pri-miR cassette at the core and 
surface target sites within the HBV cccDNA, which should result in viral-
promoter driven pri-miR expression. The pri-miRs are then processed to form 
mRNA, which forms a complex with RISC and silences HBx. The combined 
silencing of HBx and disruption of the cccDNA target sites should result in 
synergistic disruption of viral replication and subsequent HBsAg expression. 
 
3.1.1 Cloning the pri-miR-31/5/8/9 cassette into pTZ-C300 and pTZ-S300 
backbones 
 
Construction of the donor template strands with the pri-miR-31/5/8/9 cassette 
for each of the TALEN targets was undertaken using standard restriction 
enzyme digest and ligation methods as discussed in the previous chapter. 
Core and Surface donor template strands were constructed by cloning a pri-
miR-31/5/8/9 cassette into pTZ-C300 and pTZ-S300 plasmids (Table 2.1) that 
contain three stop codons flanked by regions that are homologous to the C and 
S TALEN target sites (received from K. Bloom) (Figure 3.1). Clones were 
screened for insertion of the pri-miR cassette and positive clones were 
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identified using a BamHI/EcoRI double digest (Chapter 2). The BamHI and 
EcoRI restriction sites flank the insertion site (Figure 3.2), therefore the double 
restriction digest yielded a positive result for the Core donor template strand 
when a 1.2 kb band was identified on a 1% agarose gel, while a positive clone 
for the Surface donor template strand was identified when the digest yielded a 
917 bp and a 283 bp band (Figure 3.3). These two bands were a result of two 
BamHI and one EcoRI restriction sites (Figure 3.2). Using these criteria, lanes 
3, 5, 6 and 10 were identified as positive clones for the C TALEN target and 
lanes 15, 17, 18, 19 and 20 were identified as positive clones for the S TALEN 
target (Figure 3.3). 
 
3.1.2 Orientation of the inserted pri-miR-31/5/8/9 cassette 
 
The pri-miR-31/5/8/9 cassette could be inserted in a forward orientation (same 
orientation as pri-miR-31/5/8/9 in pCI-pri-miR-31/5/8/9) or a reverse orientation. 
Pri-miR-31/5/8/9 in reverse orientation may affect pri-miR expression, thus 
determination of the insert’s orientation within the positive C and S TALEN 
target clones is necessary to ensure that the pri-miR would function correctly 
once inserted at the core and surface target sites. To ascertain orientation the 
use of a second restriction digest with NheI and PciI was warranted. The NheI 
site varies for each orientation of the insert and PciI is a unique restriction site 
in the pTZ-C300 and pTZ-S300 plasmids (Figure 3.4). The NheI/PciI double 
restriction digest of the positive clones resulted in two pairs of bands for the 
forward and reverse orientation respectively. The 4500 bp bands at the top 
consist of plasmids that were not fully digested (sample concentrations were 
too high). The plasmids were completely digested where this third band is 
absent (lane 3). A positive result for the Core and Surface donor template 
strands with a pri-miR-31/5/8/9 cassette in the forward orientation yielded a 
≈1300 bp and 2796 bp band on a 1% agarose gel (Figure 3.5). Using this 
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criterion, lanes 2, 4, 5, 10, 14, 15 and 16 were identified as negative clones for 
the C and S TALEN targets and lanes 3, 11, 12, 13 and 19 were identified as 
positive clones for both the C and S TALEN targets. These positive clones can 
be used as templates to construct linear double stranded donor template 
strands. Core clone D (lane 5) and Surface clone C (lane 15) were sequenced 
and selected for PCR amplification of the donor template strands. 
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Figure 3.1: Donor template strand with pri-miR-31/5/8/9 cassette. A pri-miR-31/5/8/9 cassette was cloned into pTZ-C300 and pTZ-S300 
plasmids (received from K. Bloom). The final donor template strand consisted of three stop codons, a pri-miR-31/5/8/9 cassette and two 300 
bp flanking sequences (homology arms) that are homologous to the C and S TALEN target sites. 
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Figure 3.2: Plasmid maps of pTZ-C300(pri-miR) and pTZ-S300(pri-miR). EcoRI and BamHI restriction sites flank the pri-miR-31/5/8/9 
insertion site. Successful insertion of the pri-miR-31/5/8/9 cassette into the pTZ-C300 (homologous to core target site) and pTZ-S300 
(homologous to surface target site) was confirmed by EcoRI/BamHI double restriction digest. An EcoRI/BamHI digest of pTZ-C300 with a pri-
miR-31/5/8/9 cassette should result in a 1.2 kb DNA band, while pTZ-S300 should yield a 917 bp and 283 bp band as it contains two BamHI 
restriction sites downstream from the insert. See Table 2.1 for plasmid descriptions. 
Chapter 3 
67 
 
                   
 
Figure 3.3: pri-miR-31/5/8/9 sequence insertion. Nine C TALEN target clones and nine S TALEN target clones were screened for 
successfully transformed clones by BamHI/EcoRI double digest. Successfully transformed Core clones yielded a 1.2 kb band (white arrow) on 
a 1% agarose gel (lanes 3, 5, 6 and 10), while successfully transformed Surface clones resulted in a 917 bp and 283 bp band (lanes 15, 17, 
18, 19 and 20) (black arrow). Core and Surface clones that were not transformed yielded 700 bp bands (lanes 2, 4, 7, 8, 9 and 16) (red arrow). 
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Figure 3.4: pri-miR-31/5/8/9 forward and reverse orientations. The plasmid maps for pTZ-S300(pri-miR) (homologous to the surface target 
site) contain a pri-miR-31/5/8/9 insert in a forward or reverse orientation. The location of PciI is the same for both orientations, while the position 
of the NheI restriction site changes depending on the insert orientation (positions 978 and 1458 for the forward and reverse orientation 
respectively). As a result, NheI/PciI double digest should yield a 1207 bp and 2796 bp band for a forward orientated insert, while an insert in 
reverse orientation should result in a 3305 bp and a 698 bp band. 
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Figure 3.5: Orientation of the pri-miR-31/5/8/9 insert. Six positive C TALEN target clones and nine S TALEN target clones were screened 
for pri-miR-31/5/8/9 insert orientation by NheI/PciI double digest. Samples were analysed on a 1% agarose gel. Core and Surface clones 
positive for NheI/PciI restriction digest resulted in approximately 1300 bp and 2796 bp bands (lanes 3, 11, 12, 13 and 19) (red arrows). The 
remaining clones were negative for NheI/PciI restriction digest and yielded a 3305 bp and a 698 bp band (lanes 2, 4, 5, 10, 14, 15 and 16) 
(black arrows). The 4500 bp bands at the top consist of plasmids that were not fully digested. The plasmids were completely digested where 
this band is absent (lane 3).
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3.1.3 Donor template strands 
 
The length of a donor template strand’s homologous regions affect HDR 
efficiency and literature suggests that linear dsDNA donor template strands for 
HDR are better recognised and incorporated at the DNA break than plasmid 
templates (124, 127, 128, 165-167, 179). Therefore, to develop these linear 
donor template strands, the pTZ-C300 and pTZ-S300 donor template plasmids 
with the forward orientated pri-miR-31/5/8/9 cassette were subjected to 
conventional PCR. Primer pairs were designed for the HBV core and surface 
target sites respectively and were used to generate linear Core and Surface 
donor template strands with flanking homologous sequences that vary in length 
(Figure 3.6). The varying lengths allowed us to determine the optimum 
homologous sequence length for HDR.  
Pri-miR-containing Core and Surface donor template strands with 50 bp 
flanking homologous regions yielded a 630 bp band on a 1% agarose gel (lanes 
2 and 6), while donor template strands with 100 bp flanking homologous 
regions yielded a 730 bp band (lanes 3 and 7) and donor template strands with 
150 bp flanking homologous regions a 830 bp band (lanes 4 and 8) (Figure 
3.7). Finally, the Core and Surface donor template strands with 300 bp flanking 
homologous regions resulted in an 1130 bp band (lanes 5 and 9). The same 
primer pairs were also used to produce linear donor template strands without 
the pri-miR-31/5/8/9 insert, which were used as pri-miR negative controls 
(Figure 3.6). Core and Surface donor template strands with 50 bp flanking 
homologous regions yielded a 130 bp band (lanes 2 and 6), while donor 
template strands with 100 bp flanking homologous regions yielded a 230 bp 
band (lanes 3 and 7) (Figure 3.8). Donor template strands with 150 bp flanking 
homologous regions yielded a 330 bp band (lanes 4 and 8) and the donor 
template strands with 300 bp flanking homologous regions resulted in an 
approximately 630 bp band (lanes 5 and 9). The band in lane 5 is slightly higher 
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than the 700 bp molecular weight marker, possibly as a result of the high 
concentration of the sample. All these bands correlated with the predicted 
amplicon sizes for each template and the developed linear donor template 
strands were used in subsequent transfection experiments.
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Figure 3.6: Core and Surface donor template strands. Donor template strands with flanking sequences that are homologous to the C and 
S TALEN target sites were generated by PCR. The length of the flanking homology arms were varied (50, 100, 150 and 300 bp respectively) 
to analyse their effect on HDR efficiency. A: Donor template strands without the pri-miR-31/5/8/9 insert were constructed as controls. B: Donor 
template strands containing the pri-miR-31/5/8/9 sequence that will be inserted at the pCH-9/3091 core and surface target sites. The primers 
are listed in Table 2.2.
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Figure 3.7: Core and Surface donor template strands containing the pri-miR-31/5/8/9 
insert. The donor template strands were generated by conventional PCR and primer pairs 
were designed for the pTZ-C300(pri-miR) and pTZ-S300(pri-miR) plasmids. Samples were 
analysed on a 1% agarose gel. Core and surface donor template strands with 50 bp and 100 
bp homologous flanking regions yielded 630 bp (lanes 2 and 6) and 730 bp (lanes 3 and 7) 
bands respectively, whereas donor template strands with 150 bp and 300 bp homologous 
flanking regions resulted in 830 bp (lanes 4 and 8) and 1130 bp (lanes 5 and 9) bands 
respectively. The donor template strands are described in Table 2.4. 
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Figure 3.8: Core and Surface donor template strands with no pri-miR-31/5/8/9 insert. The 
donor template strands were generated by conventional PCR, using the pTZ-C300 and pTZ-
S300 plasmids as templates. Samples were analysed on a 1% agarose gel. Core and surface 
donor template strands with 50 bp homologous flanking regions yielded a 130 bp band (lanes 
2 and 6), while donor template strands with a 100 bp homologous flanking region resulted in a 
230 bp band (lanes 3 and 7). Donor template strands with 150 bp and 300 bp homologous 
flanking sequences resulted in 330 bp (lanes 4 and 8) and 700 bp (lanes 5 and 9) bands 
respectively. Donor template strands are described in Table 2.4. 
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3.2 Effect of transfected donor template strands and TALEN pairs on 
HBsAg concentration 
 
The effect of the donor template strands and previously described anti-HBV 
activity of the C and S TALEN pairs was assessed using a Huh7 cell model that 
supports viral replication when transfected with HBV DNA. In this model pCH9-
3091, an HBV replication competent plasmid that actively expresses the viral 
pgRNA and sgRNAs required for HBV replication, is transiently co-transfected 
with the TALEN pairs and donor template strands into Huh7 cells. Successful 
transfection was established by GFP expression in control wells and anti-HBV 
activity was evaluated using HBsAg ELISA. HBsAg, HBV surface proteins that 
are essential for formation of the viral envelope, is an immunological marker of 
HBV infection and can be measured with HBsAg ELISA. It follows that a 
reduction in HBsAg concentration indicates a decrease in HBV replication, 
therefore, HBsAg concentration can be used to assess the efficiency of 
TALEN- and HDR-mediated disruption of HBV replication. 
 
3.2.1 C and S TALENs reduce HBsAg expression 
 
C and S TALENs create DSBs at the pCH-9/3091 core and surface target sites. 
These DSBs are repaired by error-prone NHEJ when donor templates are 
absent and result in gene disruption. Our HBsAg knockdown efficiency by 
these C and S TALENs were consistent with the results reported by Bloom et 
al. (15). Transfecting Huh7 cells with the C TALENs resulted in no significant 
HBsAg knockdown (p=0.1857), as the C TALENs target the viral core ORF and 
not the viral surface ORF (Figure 3.9). In contrast to C TALENs, transfection 
with S TALENs resulted in approximately 80% reduction in HBsAg expression 
(Figure 3.10). S TALENs are more effective in reducing HBsAg expression, as 
they target the viral surface ORF that encodes HBsAg. A left S TALEN with an 
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inactive FokI domain was used to assess the effect of transfection on HBsAg 
concentrations and did not result in significant decreased HBsAg expression 
(p=0.5358), confirming that a decrease in HBsAg concentration is a result of 
TALEN activity. 
 
3.2.2 Transfection with the Core and Surface donor template strands 
reduce HBsAg expression 
 
We did not expect significant HBsAg knockdown when transfecting cells with 
the donor template strands and no TALENs. The donor template strands are 
not able to express pri-miR, as they do not contain a promoter sequence. Any 
reduction in HBsAg expression should thus be a result of pri-miR-31/5/8/9 
integration into pCH-9/3091.  
Little or no HBsAg knockdown was observed when transfecting with either the 
Core or Surface donor template strands without the pri-miR insert (Figure 3.9 
and 3.10). The Core donor template strands without the pri-miR insert resulted 
in 0-24% decrease in HBsAg expression, while the Surface donor template 
strands without the pri-miR insert reduced HBsAg expression by 15-25%. This 
decrease in expression when introducing the donor template strands without 
the TALENs should be expected and may likely be a result of dsDNA or ssDNA 
damage repair and spontaneous recombination. Low frequencies (1 in 1000) 
of spontaneous recombination has previously been used to incorporate artificial 
DNA sequences at specific genome target sites (189-192). ssDNA damage to 
the pCH-9/3091 plasmid may occur naturally and a single stranded DNA break 
(SSB) in the path of a replication fork can be converted to a DSB and result in 
replication fork collapse. dsDNA damage to pCH-9/3091 is the result of these 
stalled replication forks and transfection stress, and can be repaired by NHEJ, 
microhomology-mediated end joining (MMEJ) and HDR. DSB repair by these 
repair mechanisms may result in spontaneous recombination and insertion of 
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the three stop codons (163, 193). This integration of the stop codons disrupts 
the target sites and effect HBsAg knockdown. The little knockdown observed 
by the Core donor template strands are consistent with the Core TALEN results 
and confirm that disruption of the core target site does not result in a significant 
decrease in HBsAg expression (p=0.1857). 
Both Core and Surface donor template strands that contain the pri-miR-
31/5/8/9 insert resulted in significant reduction in HBsAg expression (p<0.0001 
in both cases) when TALENs were absent (Figure 3.11 and 3.12). As discussed 
in the previous paragraph, the decreased HBsAg expression may be a result 
of spontaneous incorporation of pri-miR-31/5/8/9 at DNA repair sites. Once the 
pri-miR cassette is inserted, pri-miR expression is driven by an HBV promoter 
(Core promoter at the core site and S2 promoter at the surface site). Pri-miR is 
cleaved by Drosha to form pre-miR, which is exported to the cytoplasm. The 
pre-miR is cleaved by Dicer and the resultant miRNA guides the RISC complex 
to the HBx site, where it prevents gene expression (Figure 1.5). HBx is 
important for HBV replication, therefore, silencing HBx will disrupt HBV 
replication and should result in decreased HBsAg expression. The Core donor 
template strands with the pri-miR insert reduced HBsAg expression by 32-42%, 
while the Surface donor template strands with the pri-miR insert resulted in 55-
60% HBsAg knockdown (Figure 3.11 and 3.12). The HBsAg reduction by the 
Core donor template strands with the pri-miR insert is significantly improved 
when compared to C TALEN mediated knockdown (p<0.0001), which resulted 
in no significant HBsAg knockdown. This decrease in HBsAg expression could 
be the result of pri-miR expression by the inserted pri-miR-31/5/8/9 cassette. 
The increased HBsAg reduction by the Core donor template strands with the 
pri-miR insert compared to the Core donor template strands without the pri-miR 
insert (p<0.0001) also supports the conclusion that pri-miR expressed by the 
inserted pri-miR-31/5/8/9 cassette results in gene silencing and subsequent 
HBsAg knockdown (Figure 1.9 and 1.11). HBsAg knockdown by the Surface 
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donor template strands with the pri-miR insert was also significantly improved 
when compared to Surface donor template strands without the pri-miR insert, 
and was slightly less effective than the S TALENs (p=0.0276) (Figure 1.10 and 
1.12). This increase in HBsAg reduction was also a possible result of pri-miR 
expression, suggesting that pri-miR expression by the integrated pri-miR 
cassette is as efficient as S TALENs in decreasing HBsAg expression. Cells 
were transfected with the pri-miR expressing pCI-pri-miR-31/5/8/9 plasmid as 
a positive control and the resultant decrease in HBsAg expression (≈85%) was 
a result of pri-miR expression and was consistent with the findings reported by 
Ely et al. (169) (Figure 3.9 and 3.10). As a negative control, cells were 
transfected with a promoter-less linear pri-miR-31/5/8/9 sequence (see Table 
2.1) that was not inserted into a plasmid (Figure 3.10). No reduction in HBsAg 
expression occurred, confirming that the pri-miR-31/5/8/9 sequence cannot 
express pri-miR on its own and successful integration of the pri-miR-31/5/8/9 
cassette is required for HBV promoter mediated pri-miR expression. 
 
3.2.3 Co-transfected donor template strands and TALEN pairs reduce 
HBsAg expression 
 
Co-transfecting cells with the donor template strands and TALENs should 
induce HDR and subsequent integration of the donor sequence. TALENs 
should increase the amount of DSBs (compared to transfection mediated 
damage) and result in increased donor insertion frequency. The increased 
insertion frequency will then result in increased target site disruption as well as 
gene silencing when the donor template strand contains the pri-miR-31/5/8/9 
cassette. 
No significant reduction in HBsAg expression was observed when co-
transfecting cells with the C TALENs and Core donor template strands without 
the pri-miR insert (p>0.4) (Figure 3.9). In this case HBsAg expression was 
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significantly higher than that of the mock HBV infection. This may be a result of 
missense mutations introduced by NHEJ at the core target site. The start of the 
HBV polymerase ORF (2307) is overlapped by the precore/core region that is 
targeted by the Core TALENs (2319) (15, 194). HBV polymerase is required 
for initiation of viral reverse transcription and the assembly of replication-
competent viral nucleocapsids, therefore, a missense mutation introduced at 
this site could result in higher surface antigen expression as a result of 
overexpression of HBV polymerase(195). This mutation may also change the 
4th and 5th amino acid in the terminal protein (TP) of HBV polymerase, which is 
essential for pgRNA encapsidation and has a protein priming capability (196, 
197). Changes in these amino acids could affect the binding of the polymerase 
to the encapsidation signal and alter the efficiency of TP initiation, resulting in 
increased viral replication (194, 198). Co-transfection with the S TALENs and 
Surface donor template strands without the pri-miR insert resulted in significant 
HBsAg knockdown (p<0.0001). The results were a significant improvement 
over transfection with the Surface donor template strands without the pri-miR 
insert (p=0.0015). However, the HBsAg reduction was slightly less than the S 
TALEN-mediated HBsAg knockdown (p=0.0086). The spacer region between 
the FokI catalytic unit and the TALE region causes TALENs to express lower 
specificity for the exact cut site (110, 199). Therefore, it is possible that the S 
TALENs may target the Surface donor template strands, as the flanking 
homologous regions are separated by only 20 bp. This would explain the slight 
decrease in HBsAg reduction, as the amount of TALENs available to cleave 
the target DNA would decrease. 
Co-transfection with C TALENs and Core donor template strands with the pri-
miR insert resulted in significant reduction (p<0.0001) in HBsAg expression 
(55-60%) when compared to the mock transfection (Figure 3.11). The 
combination of the pri-miR-containing Core donor template strand with 50 bp 
flanking homologous regions and C TALENs was the most effective and 
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decreased HBsAg expression by 60% (p<0.0001). The HBsAg knockdown was 
also significantly improved compared to the Core donor template strands with 
the pri-miR insert and no TALENs (p<0.0001), indicating that TALEN-mediated 
DSBs likely result in increased pri-miR-31/5/8/9 integration and expression. 
Transfection with the negative control pri-miR-linear sequence and S-TALENs 
reduced HBsAg expression by approximately 75% and was not significantly 
different from S TALEN-mediated HBsAg knockdown (p=0.5388). This 
supports the previous findings that the pri-miR-31/5/8/9 cassette has to be 
inserted at the target site to result in HBV promoter driven pri-miR expression 
and subsequent silencing of HBx. The S TALENs and Surface donor template 
strands with the pri-miR insert resulted in >85% decrease in HBsAg expression 
(Figure 3.12). The pri-miR-containing donor template strands with 100 bp 
flanking homologous regions and S TALENs were the most effective and 
resulted in 93% HBsAg knockdown, a significant improvement over S TALENs 
without the donor template strands (p=0.0039). The HBsAg knockdown was 
not significantly different from the pCI-pri-miR-31/5/8/9 positive control 
(p=0.6555) (Figure 3.12). However, cells transfected with pCI-pri-miR-31/5/8/9 
were saturated with pri-miR, while cells transfected with TALENs and donor 
template strands possibly resulted in limited pri-miR-31/5/8/9 integration and 
subsequent lower pri-miR expression. This suggests that pri-miR mediated 
genome silencing should be effective even at low concentrations and may be 
improved by increasing integration of the pri-miR-31/5/8/9 cassette and 
subsequent pri-miR expression. These observations warrant further 
optimisation of our method. 
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Figure 3.9: C TALEN and Core donor template strand (without pri-miR) mediated 
knockdown of HBsAg in Huh7 cells. The mock represents baseline HBsAg expression and 
the C TALEN controls did not significantly affect HBsAg concentration. The inactive TALEN 
was a control for transfection mediated changes in HBsAg expression and did not result in 
reduced HBsAg expression. pCI-pri-miR-31/5/8/9 was used as a positive control for pri-miR 
expression and resulted in significant HBsAg knockdown. Cells were transfected with donor 
template strands that did not contain the pri-miR cassette. These donor template strands 
resulted in small changes in HBsAg concentration. Donor template strands were co-
transfected with C TALENs to assess their combined effect on HBsAg concentration and 
resulted in an increase in HBsAg concentration. HBsAg concentrations were measured by 
HBsAg ELISA. The results were averaged and the values are relative to the mock HBV 
infection. Means are indicated with SEM. All readings were done in triplicate or more, except 
pCI-pri-miR-31/5/8/9, which only had two readings. (**: p<0.01;***: p<0.001; ns: not 
significant) 
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Figure 3.10: S TALEN and Surface donor template (without pri-miR) strand mediated 
knockdown of HBsAg in Huh7 cells. The mock represents baseline HBsAg expression. The 
S TALEN controls resulted in significant reduction of HBsAg concentration, while the inactive 
TALEN did not result in decreased HBsAg expression and acted as a control for transfection 
mediated changes in HBsAg expression. A linear pri-miR-31/5/8/9 cassette increased HBsAg 
concentrations while S TALENs and the linear cassette resulted in decreased HBsAg 
concentrations. pCI-pri-miR-31/5/8/9 was used as a positive control for pri-miR expression and 
resulted in a significant decrease in HBsAg concentration. All Surface samples (with and 
without S TALENs) resulted in significant knockdown (red line). HBsAg knockdown for the 
positive control was not significantly different from that of the linear pri-miR-31/5/8/9 and 
TALEN combination. Donor template strands that did not contain the pri-miR cassette caused 
small changes in HBsAg concentration, while co-transfecting donor template strands with S 
TALENs resulted in an increase in HBsAg concentration. HBsAg concentrations were 
measured by HBsAg ELISA. The results were averaged and the values are relative to the mock 
HBV infection. Means are indicated with SEM. All readings were done in triplicate or more, 
except pCI-pri-miR-31/5/8/9, which only had two readings. (***: p<0.001; ns: not significant) 
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Figure 3.11: C TALEN and Core donor template strand (with pri-miR) mediated 
knockdown of HBsAg in Huh7 cells. The mock represents baseline HBsAg expression. C 
TALEN controls did not significantly affect HBsAg concentration and the inactive TALEN did 
not result in reduced HBsAg expression. pCI-pri-miR-31/5/8/9 was used as a positive control 
for pri-miR expression and resulted in significant HBsAg knockdown. All Core samples (with 
and without C TALENs) resulted in significant knockdown (red line). Cells were transfected with 
donor template strands that contained the pri-miR cassette, which resulted in a significant 
reduction in HBsAg concentrations when TALENs were absent. Donor template strands co-
transfected with C TALENs significantly improved HBsAg knockdown when compared to donor 
template strands without TALENs. HBsAg concentrations were measured by HBsAg ELISA. 
The results were averaged and the values are relative to the mock HBV infection. Means are 
indicated with SEM. All readings were done in triplicate or more, except pCI-pri-miR-31/5/8/9, 
which only had two readings. (**: p<***: p<0.001; ns: not significant) 
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Figure 3.12: S TALEN and Surface donor template strand (with pri-miR) mediated 
knockdown of HBsAg in Huh7 cells. The mock represents baseline HBsAg expression. S 
TALEN controls resulted in significant reduction of HBsAg concentration, while the inactive 
TALEN (TALEN negative control) did not result in a significant decrease in HBsAg expression. 
A linear pri-miR-31/5/8/9 cassette increased HBsAg concentrations while S TALENs and the 
linear cassette resulted in decreased HBsAg concentrations that were not significantly different 
from TALEN-mediated knockdown. pCI-pri-miR-31/5/8/9 was used as a positive control for pri-
miR expression and resulted in a significant decrease in HBsAg concentration. All Surface 
samples (with and without S TALENs) resulted in significant knockdown (red line). The HBsAg 
knockdown by co-transfected TALENs and donor template strands was a significant 
improvement compared to the TALEN control and donor templates without TALENs, but was 
similar to pCI-pri-miR-31/5/8/9 mediated HBsAg knockdown. HBsAg concentrations were 
measured by HBsAg ELISA. The results were averaged and the values are relative to the mock 
HBV infection. Means are indicated with SEM. All readings were done in triplicate or more, 
except pCI-pri-miR-31/5/8/9, which only had two readings. (***: p<0.001; ns: not significant) 
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3.3 pri-miR-31/5/8/9 cassette integration at the pCH-9/3091 core and 
surface target sites 
 
Integration of the pri-miR-31/5/8/9 cassette should result in pri-miR expression 
that is driven by an HBV promoter. Therefore, successful insertion of the pri-
miR-31/5/8/9 cassette has to be confirmed to determine if insertion of the pri-
miR-31/5/8/9 cassette could result in HBV promoter driven pri-miR expression 
and subsequent HBsAg knockdown. In this project conventional PCR and DNA 
sequencing were used to assess insertion of the pri-miR-31/5/8/9 cassette at 
the core and surface target sites. To evaluate insertion, primer pairs were 
designed to amplify the core and surface insertion sites respectively (Figure 
3.13). The forward primer binds to a sequence located within the inserted 
artificial sequence while the reverse primers bind to a sequence downstream 
from the right homologous region. These primers were designed to prevent 
amplification of the donor template strands and should ensure that amplification 
only occurs when the insert is present at the target sites. Multiple controls were 
introduced to confirm that these primers do not amplify the donor templates or 
any of the other co-transfected plasmids. 
 
3.3.1 PCR analysis of pri-miR-31/5/8/9 insertion at the core target site 
 
pCH-9/3091 and pri-miR-containing Core donor template strands were used as 
PCR controls to confirm that the correct donor template strands were used for 
transfection and that the Core primer pair (Table 2.6) does not amplify pCH-
9/3091 or the donor template strands (Figure 3.14). The Core donor template 
strands with 50 bp flanking homologous regions yielded a 630 bp band (lane 
2), while the donor with the 300 bp homologous regions resulted in a ≈1200 bp 
band (lane 3) on a 1% agarose gel. These donor template strand sizes were 
consistent with the PCR results in 3.1.3 (Figure 3.3), indicating that the correct 
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donor template strands were used for transfection. PCR was performed on the 
pCH-9/3091 plasmids as well as the donor template strands and did not result 
in DNA bands (lanes 4, 5 and 6), confirming that the Core primer pair does not 
amplify the pCH-9/3091 plasmids or Core donor template strands. PCR of the 
pCH-9/3091 plasmids purified from transfected Huh7 cells (Table 2.5) resulted 
in an 1100 bp band (lanes 7, 8, 9 and 10) and confirms that the pri-miR-31/5/8/9 
cassette was successfully incorporated at the core target site in all four 
transfected samples. The 1100 bp bands in lanes 7 and 9 support the 
hypothesis that DNA is damaged during transfection and that insertion of the 
pri-miR cassette occur even in the absence of TALENs. A 500 bp band was 
also present in lane 9 and 10 and may be a result of primers that do not bind 
exclusively to their designed targets. It is possible that other recombination 
events occurred as a result of NHEJ and MMEJ. HDR and these recombination 
events may result in partial insertion of the artificial sequence and yield PCR 
products with different lengths. Potentially only small sections of the artificial 
sequence are needed to allow NHEJ, MMEJ and HDR-mediated dsDNA repair. 
Nakade et al. also demonstrated that precise HDR mediated integration occurs, 
but that not all inserted sequences contain the complete donor sequence (200). 
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Figure 3.13: Analysis of pri-miR-31/5/8/9 integration at the core target sites. A forward 
primer binds a target sequence within the region containing the three stop codons and a 
reverse primer binds a downstream target sequence within the pCH-9/3091 plasmid. The 
primer pair should not amplify the donor template strands and should only yield products if the 
insert is present in the pCH-9/3091 plasmid. 
 
 
 
Figure 3.14: PCR analysis of the core target site. The control bands in lanes 2 and 3 are 
consistent with the size of the C50(pri-miR) and C300(pri-miR) donor templates in Figure 3.3 
and were used as positive controls to confirm transfection with the correct donor template 
strands. None of the negative controls resulted in DNA bands (lanes 4, 5 and 6), confirming 
that the TALEN pair does not amplify pCH-9/3091 or the donor template strands. A ≈1100 bp 
band in lanes 7, 8, 9 and 10 confirms that the pri-miR-31/5/8/9 cassette was successfully 
integrated at the core target site. The identity of the 500 bp band in lanes 9 and 10 is unknown. 
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3.3.2 PCR analysis of pri-miR-31/5/8/9 insertion at the surface target 
site 
 
The negative controls for the Surface primer pair consisted of pCH-9/3091 and 
pUC118 samples (lanes 3 and 4) (Figure 3.16). These samples were amplified 
with Surface primer pairs (Table 2.6) and did not yield DNA bands, confirming 
that the primer pair does not amplify these plasmids (Figure 3.16). PCR of the 
insert-containing Surface donor template strands (negative control) resulted in 
an 800 bp band (lanes 5 and 6) when no bands were predicted. The primers 
and donor template strands were purified to rule out contamination (no DNA 
band in dH2O: lane 2), but still resulted in 800 bp PCR products. Thus, these 
bands indicate that the Surface primers could be binding to off-site sequences. 
Purified plasmids from cells that were only transfected with pCH-9/3091 
plasmids also acted as negative controls and did not yield DNA bands (lanes 8 
and 9). Successful insertion of the pri-miR-31/5/8/9 cassette results in a 1200 
bp band. Using this criterion, successful insertion was confirmed in cells 
transfected with Surface donor template strands and S TALENs (lanes 10, 11, 
12 and 13). However, the bands were very light, a possible result of a low 
insertion frequency or poor PCR efficiency. Another unknown 800 bp band was 
observed in lanes 11 and 13 and support the possibility that the primers are 
binding to off-site sequences. The multiple bands also support the PCR results 
in 3.3.1 that yielded multiple bands in the Core samples, and reinforces the 
hypothesis that alternative or partial recombination events are occurring. These 
800 bp bands were sequenced to determine their identity. 
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Figure 3.15: Analysis of pri-miR-31/5/8/9 integration at the surface target sites. A forward 
primer binds a target sequence within the region containing the three stop codons and a 
reverse primer binds a downstream target sequence within the pCH-9/3091 plasmid. The 
primer pair should not amplify the donor template strands and should only yield products if the 
insert is present in the pCH-9/3091 plasmid. 
 
 
 
Figure 3.16: PCR analysis of the surface target site after transfection. The negative 
controls in lanes 2, 3 and 4 did not yield DNA bands and confirm that the primer pair does not 
amplify pCH-9/3091 or pUC118. The control samples in lanes 5 and 6 resulted in an 
unidentified 800 bp band. No DNA bands were visible in the experimental samples without 
donor template strands (lanes 8 and 9), also confirming that the primer pair does not amplify 
pCH-9/3091. Successful insertion of the pri-miR-31/5/8/9 cassette at the surface target site 
resulted in light 1200 bp bands (lanes 10, 11, 12 and 13). An unknown 800 bp band was also 
present in two of the experimental samples (lanes 11 and 13). 
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3.3.3 Sequencing of the pri-miR-31/5/8/9 insertion site 
 
PCR results are not sufficient to confirm pri-miR-31/5/8/9 insertion at the target 
sites and warrants the use of a more precise analysis method such as 
sequencing. Sequencing provides the exact nucleotide sequence at the insert 
sites and can be compared to the pCH-9/3091 and pri-miR-31/5/8/9 sequences 
to confirm insertion of the pri-miR-31/5/8/9 cassette. Therefore, the 1000 bp 
amplicon from the Core PCR analysis (Figure 3.14: lanes 7, 8, 9 and 10) and 
the 1200 bp and 800 bp amplicons from the Surface PCR analysis (Figure 3.16: 
lanes 5, 6, 10, 11, 12 and 13) were extracted from the agarose gels and 
sequenced by Inqaba Biotech (Pretoria, Gauteng, South Africa). BLAST 
sequence alignments were performed to compare the sequencing results to 
the pCH-9/3091 sequence with the pri-miR-31/5/8/9 cassette at the core and 
surface sites (187, 188). 
 
The 1000 bp Core amplicon contained the pri-miR-31/5/8/9 cassette 
 
The complete pri-miR-31/5/8/9 cassette, a stop codon and a section of the 
pCH-9/3091 were present in the sequencing results of the 1000 bp Core 
sample (Figure 3.17). These results are consistent with the PCR results (Figure 
3.14) and confirm that co-transfecting cells with C TALENs and pri-miR-
containing Core donor templates with 50 bp and 300 bp flanking homologous 
regions result in HDR and subsequent integration of the pri-miR-31/5/8/9 
cassette at the core target site. The results also support the hypothesis that 
non-specific DSBs caused by transfection and collapsed replication forks are 
repaired by HDR, which successfully inserts the pri-miR-31/5/8/9 cassette at 
the core target site when the Core donor template strands with the pri-miR 
insert and no TALENs are introduced. 
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Sequencing results of the 800 bp Surface amplicon 
 
The sequencing results of the 800 bp PCR product from the Surface PCR 
analysis (Figure 3.16: lanes 5, 6, 11 and 13) confirmed that the pri-miR-31/5/8/9 
cassette and three stop codons were not integrated at the surface target site 
(Figure 3.18). 
 
Sequencing results of the 1200 bp Surface amplicon 
 
The expected size of the amplified insertion site with the pri-miR-31/5/8/9 
cassette was 1200 bp. This 1200 bp PCR product from the Surface sample 
(Figure 3.16: lanes 10, 11, 12 and 13) was sequenced twice. Both results 
confirmed that the stop codons and pri-miR-31/5/8/9 cassette were not 
incorporated at the surface target site. The short sequence length (540 bp) 
suggests that sequencing may have been incomplete or the forward PCR 
primer bound to a sequence further downstream within the right flanking 
homologous region of the surface target site (Figure 3.19). This would support 
the idea that the forward primer does not bind exclusively to its designed 
surface target. 
 
Partial insertion of the artificial sequence at the surface site 
 
The purified plasmids of cells transfected with the Surface donor template 
strands and S TALENs (Figure 3.16: lanes 10, 11, 12 and 13) were amplified 
(PCR) and sequenced by Inqaba Biotech (Pretoria, Gauteng, South Africa) to 
confirm that the absence of the stop codons and pri-miR cassette is not the 
result of a fault in the PCR protocol. The new results confirmed that two stop 
codons were successfully integrated at the surface target site, but the pri-miR-
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31/5/8/9 cassette was absent (Figure 3.20). This reinforces the hypothesis that 
HDR, NHEJ and MMEJ can repair DSBs by only partially inserting the artificial 
sequence. This suggests that only small sections of the artificial sequence are 
needed to allow NHEJ, MMEJ and HDR-mediated dsDNA repair, thus 
supporting the results reported by Nakade et al. (200). However, this surface 
sample is not a representative of the whole and it is possible that complete 
integration of our artificial sequence occurs at a very low frequency and is 
beyond the detection level of the PCR. This problem might be resolved by 
increasing the number of transfected cells. An increase in cells will allow larger 
amounts of pCH-9/3091, TALENs and donor template strands to be transfected 
and may result in an increase in insertion frequency that is detectable by PCR. 
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Figure 3.17: Sequence alignment of the 1000 bp Core sample and pri-miR-containing 
pCH-9/3091. The yellow highlighted area indicates the integrated pri-miR-31/5/8/9 cassette 
and a stop codon at the core target site. The blue highlighted area represents the right 
homologous region. A partial pCH-9/3091 sequence at the end confirms that the sequencing 
results are from pCH-9/3091 and not the donor template strands. K: Keto (G or T); R: Purine 
(A or G); Y: Pyrimidine (C or T); W: Weak (A or T); M: Amino (A or C). 
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Figure 3.18:  Sequence alignment of the 800 bp Surface sample and pri-miR-containing 
pCH-9/3091. The blue highlighted area indicates the right homologous region. A partial pCH-
9/3091 sequence at the end confirms that the sequencing results are from pCH-9/3091 and 
not the donor template strands. Integration of the pri-miR-31/5/8/9 cassette did not occur. S: 
Strong (G or C); Y: Pyrimidine (C or T). 
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Figure 3.19: Sequence alignment of the 1200 bp Surface sample and pri-miR-containing 
pCH-9/3091. The sequence length of the 1200 bp is short (540 bp) and the blue highlighted 
area indicates the right homologous region with a missing upstream section. A partial pCH-
9/3091 sequence at the end confirms that the sequencing results are from pCH-9/3091 and 
not the donor template strands. Integration of the pri-miR-31/5/8/9 cassette did not occur. M: 
Amino (A or C). 
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Figure 3.20: Sequence alignment of the pri-miR-31/5/8/9 surface insertion site and pri-
miR-containing pCH-9/3091. The yellow highlighted section contains two stop codons and 
the blue highlighted region indicates the right homologous region. The pri-miR-31/5/8/9 
cassette was not inserted, confirming that only partial insertion occurred at the surface site. A 
partial pCH-9/3091 sequence at the end confirms that the sequencing results are from pCH-
9/3091 and not the donor template strands. 
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3.4 Pri-miR expression 
 
Ely et al., demonstrated that the pri-miR-31/5/8/9 cassette results in efficient 
HBsAg reduction (169). Therefore, we proposed that inserting the pri-miR 
cassette at the pCH-9/3091 core and surface sites should result in pri-miR 
expression and subsequent HBsAg knockdown. This pri-miR expression by the 
incorporated pri-miR-31/5/8/9 cassette was assessed by Northern blot, a 
technique that detects specific RNA or miRNA in a sample. 
 
3.4.1 Cloning donor template strands into pTZ57 R/T  
 
PCR is not sufficient to produce the large quantities of donor template strands 
required for pri-miRNA detection. Therefore, the donor template strands were 
cloned into pTZ57 R/T plasmids for large scale plasmid production. The 
C50(pri-miR) and S100(pri-miR) donor template strands with the pri-miR insert, 
and the pri-miR-31/5/8/9 cassette were each cloned into pTZ57 R/T plasmids. 
Positive clones were identified with a PvuII restriction digest (Chapter 2) as the 
PvuII restriction sites flanked the inserted sequence (Figure 3.21). Successful 
insertion of the Core donor template strand yielded a 1015 bp band (lane 2), 
while successful insertion of the Surface template resulted in a 1115 bp band 
(lane 3) (Figure 3.22). An 898 bp band confirmed successful insertion of the 
pri-miR-31/5/8/9 cassette (lane 4). These positive clones were maxi prepped 
and used in transfection experiments. 
 
3.1.1 Northern blot 
 
If the pri-miR-31/5/8/9 cassette is integrated at the target site, the HBV 
promoter should drive the pri-miR expression. The pri-miR is then processed 
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to miRNA by the RNA interference pathway. This miRNA can be detected by 
Northern blot and can be visualised to confirm that pri-miR is being expressed. 
Northern blot results that are positive for pri-miR expression will support the 
idea that pri-miR expression is driven by an HBV promoter when the pri-miR-
31/5/8/9 cassette is integrated into pCH-9/3091. It will also support the 
hypothesis that pri-miR expression by the integrated cassette results in HBsAg 
knockdown. A miR-31/5 guide probe oligonucleotide (169) was used to probe 
for pri-miR-31/5/8/9, and purified pri-miR-31/5/8/9 was used as a positive 
control to confirm probe activity. The positive control resulted in a ≈20 bp band 
and confirmed that the probe was active and that the Northern blot protocol 
was successful (Figure 3.23). None of the experimental samples resulted in 
bands. No band was expected for pri-miR-31/5/8/9, pTZ-pri-miR or pTZ-pri-miR 
with TALENs, as HBsAg ELISA results suggested that the linear pri-miR-
31/5/8/9 sequence did not result in pri-miR expression (see Figure 3.9). The 
absence of bands in the remaining samples may be due to the low insertion 
frequency of the pri-miR cassette and subsequent low concentrations of RNA. 
Low concentrations of pri-miR should be enough to cause reduction in HBsAg 
expression, suggesting that the miRNA concentrations are high enough to 
effect change in HBsAg expression, but are not sufficient to be detected by 
Northern blot. This inability to detect the RNA warrants the use of more 
sensitive RNA detection methods. 
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Figure 3.21: pTZ57 R/T plasmids containing the pri-miR-31/5/8/9 cassette and the 
C50(pri-miR) and S100(pri-miR) donor template strands. C50(pri-miR), S100(pri-miR) and 
pri-miR-31/5/8/9 were cloned into pTZ57 R/T by TA cloning. Two PvuII restriction sites flank 
the insertion sites, therefore a PvuII restriction digest was performed to confirm successful 
integration of C50(pri-miR), S100(pri-miR) and pri-miR-31/5/8/9 into the pTZ57 R/T plasmids.  
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Figure 3.22: C50, S100 and pri-miR31/5/8/9 cloned into pTZ57 R/T. All samples were 
digested with PvuII and analysed on a 1% agarose gel. Restriction digest with PvuI resulted in 
1015 bp, 1115 bp and 898 bp bands for pTZC50, pTZS100 and pTZ-pri-miR-31/5/8/9 clones 
respectively.  
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Figure 3.23: Northern blot membrane probed for pri-miR expression. A miR-31/5 guide 
probe oligonucleotide was used to probe for miRNA expressed by the integrated pri-miR-
31/5/8/9 cassette. Samples were analysed on a 15% acrylamide gel. The pri-miR-31/5/8/9 in 
the control resulted in an ≈20 bp band (black arrow). pCI-pri-miR-31/5/8/9 was a positive control 
for pri-miR expression, but did not yield a band. No band was expected for pri-miR-31/5/8/9, 
pTZ-pri-miR or pTZ-pri-miR with TALENs, as these sequences and plasmids should not result 
in pri-miR expression (see Figure 3.9). The remaining experimental samples did not yield any 
bands, possibly due to low insertion frequency 
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4. Discussion 
 
4.1 Disruption of HBV replication through HDR 
 
A novel therapeutic design is required to treat and eliminate chronic hepatitis 
B virus (HBV) infections. Chronic HBV remains a major challenge for hyper-
endemic areas such as Sub-Saharan Africa and Asian countries, therefore, 
development of affordable and effective treatments remains a top research 
priority (1). Multiple vaccines are currently available and effectively prevent 
HBV infection. However, these vaccines do not treat existing HBV infections 
(25). There are currently various treatments available that successfully manage 
HBV infections. However, these treatments target viral post transcriptional 
mechanisms to inhibit HBV and, as a result of persistent cccDNA, do not clear 
the virus, necessitating continuous treatment (13, 50, 51, 63, 64). Viral cccDNA 
avoids treatment as well as the host immune response and results in latent or 
occult infection. Therefore, a novel treatment that targets viral cccDNA is 
required to eradicate the viral reservoirs and successfully clear HBV. 
Manipulation of viral DNA and RNA by designer nucleases allows targeting of 
the pre- and post-transcriptional events in the viral life cycle and shows promise 
as anti-viral agents against HBV (63, 76-78). It follows then that designer 
nucleases, such as TALENs and ZFNs, may be used to target the viral cccDNA 
reservoirs. 
 
Both TALENs and ZFNs have recently been used to manipulate genomes of 
various organisms and cell lines (79, 103, 108, 125, 129-131). Designer 
TALENs can target a wide range of targets and are able to discriminate 
between highly similar sequences, making it a very precise genome editing tool 
(85, 132). Preliminary studies also indicated that little or no off-target 
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mutagenesis occurs  and concluded that incidence of off-target effects is not a 
significant concern for disease modelling and genome-editing applications 
(135-137). Thus, TALENs provide highly specific and efficient genome-editing 
abilities. The FokI domains of a TALEN pair dimerise and cleave a target DNA 
sequence, resulting in a DSB that is repaired by HDR, NHEJ or microhomology-
mediated end joining (MMEJ). These repair pathways may introduce mutations 
and result in disruption of the target site. Researchers recently demonstrated 
that introduction of a homologous donor template strand induces the HDR 
pathway and results in integration of an artificial sequence at the DSB, 
confirming that these repair pathways can be exploited for precise genome 
engineering (163-167). 
 
It is difficult to target the viral cccDNA, as precise targeting of the genome is 
required to prevent off-target cleavage that may harm the host. Recently 
researchers reported success in targeting HBV cccDNA with ZFNs and 
TALENs (15, 177). They managed to significantly reduce viral protein 
expression and genome replication both in vitro and in vivo, but were unable to 
eliminate the viral cccDNA pool. This might be a result of viral mutagenesis, 
epigenetic regulation or NHEJ repair of the TALEN-mediated DSBs. NHEJ is 
error prone and results in mutagenesis at the target site, but can also 
successfully repair DSBs, allowing cccDNA to persist and cause latent infection 
once treatment is suspended. Alternative gene therapies, such as RNA 
interference, also demonstrated significant anti-HBV activity (169, 201-206). 
Ely et al. designed a pri-miR expression cassette that expressed anti-HBV pri-
miRs and successfully disrupted HBV replication (169). Therefore, we 
proposed combining TALENs and these pri-miR cassettes to target both the 
cccDNA reservoirs and HBV replication. TALENs would create DSBs and the 
introduction of donor template strands containing a promoter-less pri-miR 
cassette will induce HDR and facilitate HDR-mediated integration of the pri-
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miR cassette at the genome target site. Successful integration disrupts the 
target site and results in HBV-promoter driven pri-miR expression. The 
resultant silencing of HBx by processed pri-miRs should inhibit HBV replication 
and prevent formation of new cccDNA pools, allowing TALENs to target and 
eliminate the existing cccDNA genomes (Figure 4.1). 
 
4.2 Combining TALENs and donor template strands significantly affect 
viral protein expression 
 
TALENs and donor template strands can be co-introduced to facilitate 
integration of the pri-miR-31/5/8/9 cassette into the HBV genome. TALENs 
should create DSBs at the HBV core and surface cccDNA targets and result in 
NHEJ, MMEJ and HDR. Our TALEN results were consistent with the results 
reported by Bloom et al., confirming that NHEJ is upregulated when DSBs are 
introduced (15). The presence of the donor template strands should increase 
or favour HDR and result in increased integration of the pri-miR cassette. 
The combination of TALENs and pri-miR-containing donor template strands 
improved viral disruption significantly. The increased insertion frequency of the 
pri-miR-31/5/8/9 cassettes at the TALEN-mediated DSBs results in increased 
pri-miR expression and subsequent gene silencing. This TALEN-donor 
template strand combination improves both pri-miR and TALEN-mediated virus 
disruption. Successful integration of the pri-miR cassette disrupts the target 
genome sequence and allows TALENs to target the remaining cccDNA 
genomes. Pri-miR expression by the integrated cassette will also inhibit viral 
replication by silencing HBx, which will prevent production of new cccDNA 
genomes. Therefore, the combination of TALENs and pri-miR should gradually 
decrease the amount of cccDNA until the latent cccDNA reservoir is depleted.
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Figure 4.1: Disrupting the HBV genome using TALENs and RNAi. TALENs cleave the HBV cccDNA and create a DSB. A donor template 
strand containing a pri-miR-31/5/8/9 cassette is introduced and TALENs are free to bind to remaining cccDNA genomes in the cccDNA pool. 
HDR then utilises the donor template strand to facilitate integration of the pri-miR-31/5/8/9 cassette at the target site. The integrated cassette 
transcribes pri-miRNA, which is processed to form a RISC/miRNA duplex which facilitates translational inhibition or endonucleolytic cleavage 
of the HBx mRNA.  
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4.2.1 The lengths of the flanking homologous regions affect HDR 
efficiency 
 
Researchers demonstrated that donor templates with longer flanking 
homologous sequences (400-800 bp) result in increased target efficiency and 
HDR frequency (167). However, some studies suggest that shorter 
homologous flanking sequence may also result in optimal HDR in some cell 
types (127, 179). Our results confirmed that shorter homologous sequences 
are more effective in Huh7 cells. This effectiveness may indicate that 
integration of the donor sequence is mediated by both HDR and MMEJ. A 
shorter homologous sequence should result in less homology search in HDR 
and may also result in preference for MMEJ. However, micro-homology regions 
are usually 9-20 bp in length, suggesting that MMEJ may recognise and use 
templates with longer homologous sequences for DNA damage repair (193). 
 
4.2.2 Upregulation of viral protein expression 
 
Error-prone NHEJ and MMEJ mediated DNA damage repair may introduce 
mutations or partially integrate the donor template strand. These genome 
modifications may result in harmful changes in protein expression. We found 
that upregulation of viral protein expression occurred when the pri-miR-31/5/8/9 
cassettes were integrated at the core site. This may also be a result of 
missense mutations introduced by NHEJ. The precore/core region that is 
targeted by the C TALENs (2319) overlaps with the start of the HBV 
polymerase ORF, which encode HBV polymerase (2307) (15, 194). A 
missense mutation at this site could affect HBsAg expression as HBV 
polymerase is essential for initiation of viral reverse transcription and the 
assembly of replication-competent viral nucleocapsids. A missense mutation 
introduced at this site could result in overexpression of HBV polymerase and 
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subsequent increased HBsAg expression (195). This mutation may also 
change the 4th and 5th amino acid in the terminal protein (TP) of HBV 
polymerase (196, 197). The TP is essential for pgRNA encapsidation and 
changes in these amino acids could affect the binding of the polymerase to the 
encapsidation signal and alter the efficiency of TP initiation (194, 196-198). 
This could result in increased viral replication and subsequent upregulation of 
HBsAg expression. These results indicate that adverse effects may occur, even 
when precise nuclease activity and HDR integration are utilised. These adverse 
effects may be harmful to the host, therefore, further investigation is required 
to optimise our method and to ensure that no adverse events occur. 
 
4.3 Donor template strand mediated knockdown of viral protein 
expression and replication 
 
We found that donor template strands without TALENs resulted in disruption of 
viral activity. HDR occurred without TALENs and integrated the anti-viral 
sequence at the genome target site, which resulted in pri-miR expression and 
subsequent silencing of HBx. This is consistent with previous methods that 
induced HDR to insert an artificial DNA sequence at a target site (189-192). It 
is possible that the HBV equivalent was damaged during transfection. This 
damage was repaired by NHEJ, MMEJ and HDR, which may have resulted in 
spontaneous recombination (163, 193). The presence of the donor template 
strands stimulates HDR and subsequent integration of the artificial sequence 
at the DNA break site. The DSBs can also be repaired by NHEJ, which repairs 
breaks at an equal or higher frequency than HDR (163). Gabriel et al. 
demonstrated that NHEJ can also insert donor sequences at DSBs and causes 
off-target insertion within close proximity of the homologous regions of the 
TALEN target sites. NHEJ insertion may also occur at unidentified locations as 
a result of non-TALEN mediated DNA damage (207). Nakade et al. also 
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demonstrated that DSB overhangs that are complementary to linear DNA 
fragments or donor template strands facilitate integration by NHEJ in zebrafish 
and cultured cells (200). Recently MMEJ has been described to insert donor 
sequences at a target site (193, 199, 200). MMEJ is an error-prone minor repair 
pathway that comprises 10-20% of cellular repair activity and shares the DSB 
end resection step with HDR (193, 199). The repair mechanism actively repairs 
DSBs at collapsed replication forks and enables integration of large DNA 
fragments in cells with low HDR activity (200). In contrast to HDR, MMEJ 
undergoes short end resection (14-18 bp) on either side of the DSBs to reveal 
microhomology regions (9-20 bp) and joins the DSB ends by pairing bases at 
these microhomology regions (193). Therefore, it is possible that the donor 
sequence can be inserted through multiple pathways. Insertion by this method 
likely occurs at very low frequencies, suggesting that pri-miR gene silencing 
significantly disrupts HBV replication even when the pri-miR-31/5/8/9 
integration frequency is low (189-192). These pathways do not necessarily 
result in complete integration of the artificial sequence, but even partial 
insertion should be enough to disrupt HBV replication. Merrihew et al. 
demonstrated that HDR can also result in off-target integration (189). This 
finding suggests that the use of these error prone pathways may have 
significant therapeutic implications, and may result in harmful mutagenesis in 
untargeted regions of the host genome. It is thus important for the findings of 
this study to be tested in more biologically relevant models allowing for more 
complete characterisation of its safety profile. 
 
4.4 Pri-miR expression by the integrated pri-miR-31/5/8/9 cassette 
 
Ely et al. demonstrated that a pri-miR-31/5/8/9 expression cassette results in 
efficient disruption of HBV replication (169). Our donor template strands 
contained the pri-miR-31/5/8/9 cassette, but lacked a promoter. We 
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hypothesised that pri-miR expression from the integrated pri-miR-31/5/8/9 
cassette should be driven by an HBV promoter. Our results suggested that pri-
miR mediated gene silencing occurred, but we were unable to visualise the 
expressed pri-miR using Northern blot hybridisation. This may be a result of 
low pri-miR-31/5/8/9 integration frequency and subsequent low pri-miR 
expression, suggesting that pri-miR expression was sufficient to affect HBV 
replication, but below the detection threshold for  Northern blot. This warrants 
further investigation using more sensitive detection methods. Increasing the 
volume of cells and amount of TALENs and donor template strands should 
increase the amount of expressed pri-miR to a level that is detectable by 
Northern blot. However, if this does not succeed, alternative methods can be 
explored. The Northern blot detection sensitivity can be improved by using 
probe sequences that contain locked nucleic acids (LNAs). Válóczi et al. 
demonstrated that oliginucleotide probes with LNAs have improved 
hybridisation properties and mismatch discrimination, making them well suited 
for accurate miRNA detection (208). These probes are easy to synthesise and 
can be used in a Northern blot analysis that uses standard end-labelling 
methods and hybridisation conditions. The probe is highly specific and its 
sensitivity is increased tenfold compared to standard Northern blot, making 
them an improved and practical alternative (208). qRT-PCR has also been 
used to detect low amounts (25 pg) of mature miRNA. Chen et al. developed a 
method that uses stem loop reverse transcription (RT) primers to hybridise to 
miRNA during the RT step in qRT-PCR (209). The RT products can then be 
quantified using conventional TaqMan PCR. The stem loop primers are more 
specific and efficient than standard primers and are not affected by genomic 
DNA contamination. Stem loop qRT-PCR is also much less time consuming 
than Northern blot. These qualities make qRT-PCR with stem loops an 
attractive alternative to Northern blot. In contrast to Northern blot, qRT- PCR 
does not determine the size of the miRNA. However, the size of our target 
miRNA has already been determined (169), therefore, quantification with qRT-
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PCR should be sufficient to confirm pri-miR expression by the integrated pri-
miR cassette. 
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5. Conclusion 
 
We confirmed the findings by Bloom et al., that TALENs can be used to 
achieve targeted disruption of the HBV genome (15). These TALENs can 
be coupled with HDR by introducing a homologous DNA template strand. 
Donor template strands can be designed to facilitate integration of a pri-
miR-31/5/8/9 cassette into the HBV genome. Introduction and integration of 
the pri-miR cassette result in miRNA processing that is sufficient for 
significant and additive HBV knockdown. The synergistic activity of TALENs 
and pri-miRNA is of significant value for the therapeutic field. Co-introducing 
TALENs and donor template strands inhibits viral replication, thus 
preventing formation of more cccDNA in new hepatic cells and allowing 
more time for TALEN-mediated inactivation of the pre-existing cccDNA pool. 
This combination could possibly replace lifelong HBV treatments by clearing 
viral cccDNA and preventing latent infection. The decrease in required 
treatment could also reduce cost on health systems of developing countries 
where chronic HBV is prevalent. TALENs and donor template strands could 
also prevent adverse symptoms caused by current HBV treatments, thus 
improving the general health of HBV patients. However, we demonstrated 
that the pri-miR cassette is also integrated by spontaneous recombination, 
raising the possibility that off-target insertion may occur. This concern 
warrants further investigation and optimisation of the method, as off-target 
insertion may result in adverse effects. However, this proof of concept study 
paves the way for expanded studies in in vivo and more advanced in vitro 
models for the development of targeted anti-HBV gene therapies. 
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